Open Access

Microarray analysis of gene expression in liver, adipose tissue and skeletal muscle in response to chronic dietary administration of NDGA to high-fructose fed dyslipidemic rats

Nutrition & Metabolism201613:63

https://doi.org/10.1186/s12986-016-0121-y

Received: 28 May 2016

Accepted: 14 September 2016

Published: 29 September 2016

Abstract

Nordihydroguaiaretic acid (NDGA), the main metabolite of Creosote Bush, has been shown to have profound effects on the core components of metabolic syndrome, including lowering of blood glucose, free fatty acids and triglyceride levels, attenuating elevated blood pressure in several rodent models of dyslipidemia, and improving body weight, insulin resistance, diabetes and hypertension. In the present study, a high-fructose diet fed rat model of hypertriglyceridemia, dyslipidemia, insulin resistance and hepatic steatosis was employed to investigate the global transcriptional changes in the lipid metabolizing pathways in three insulin sensitive tissues: liver, skeletal muscle and adipose tissue in response to chronic dietary administration of NDGA. Sprague-Dawley male rats (SD) were fed a chow (control) diet, high-fructose diet (HFrD) or HFrD supplemented with NDGA (2.5 g/kg diet) for eight weeks. Dietary administration of NDGA decreased plasma levels of TG, glucose, and insulin, and attenuated hepatic TG accumulation. DNA microarray expression profiling indicated that dietary administration of NDGA upregulated the expression of certain genes involved in fatty acid oxidation and their transcription regulator, PPARα, decreased the expression of a number of lipogenic genes and relevant transcription factors, and differentially impacted the genes of fatty acid transporters, acetyl CoA synthetases, elongases, fatty acid desaturases and lipid clearance proteins in liver, skeletal muscle and adipose tissues. These findings suggest that NDGA ameliorates hypertriglyceridemia and steatosis primarily by inhibiting lipogenesis and enhancing fatty acid catabolism in three major insulin responsive tissues by altering the expression of key enzyme genes and transcription factors involved in de novo lipogenesis and fatty acid oxidation.

Keywords

Fatty acid oxidation Lipogenesis Steatosis Hypertriglyceridemia CD36 L-FABP Malony-CoA decarboxylase

Background

Nonalcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease [13], is a major health problem worldwide [2, 4]. NAFLD encompasses a spectrum of disease ranging from simple steatosis (excessive accumulation of fat mainly in the form of triglycerides [57]), nonalcoholic steatohepatitis (NASH) that includes steatosis along with inflammation and fibrosis and end-stage disease, cirrhosis and liver failure [8, 9] and a subsequent potential for hepatocellular carcinoma [10]. During the past few decades, the prevalence and severity of NAFLD have been paralleled with that of obesity, type 2 diabetes and metabolic syndrome (MetS) [4, 11, 12] and many studies have reported a pathophysiologic association between NAFLD and these disorders [1118]. MetS is the umbrella description given to a number of derangements including insulin resistance and glucose intolerance, (central) obesity, dyslipidemia, and hypertension [1921]. NAFLD is closely tied to insulin resistance and hepatic dyslipidemia and is now considered as a hepatic manifestation of MetS [12, 1417]. The current evidence indicates NAFLD is an independent risk factor for the development of type 2 diabetes [13, 17, 18] and cardiovascular disease [12, 2224]. Currently, there are no designated therapies in the clinical management of NAFLD except lifestyle modification including weight reduction, diet and exercise, which are hard to comply with on a long-term schedule [2527].

Although the exact cause of the rising prevalence of NAFLD is not fully understood, the rapid urbanization, over-nutrition (consumption of high-carbohydrate and high-fat calorie-rich diets), increasing consumption of sugar sweetened (such as sucrose [cane or beet sugar] and high-fructose corn syrup [HFCS]) caloric beverages (i.e., soft-drinks and colas) and increasingly sedentary lifestyles, all have been linked with the increasing incidence of this disease [2833]. In recent years, considerable attention has been paid to the contribution of dietary carbohydrates, sugar-sweetened beverages and monosaccharide fructose, in particular, in the pathogenesis of NAFLD [28, 30, 32, 34, 35]. The role of fructose in NAFLD (steatosis) pathogenesis has received a great deal of attention in part because from 1999 to 2004 the consumption of fructose increased by ~32 % [36]. HFCS now represents nearly 50 % of caloric sweeteners used in the United States [37]. Hepatic fructose metabolism differs from glucose [35, 38], and, in a hypercaloric setting, fructose induces hypertriglyceridemia and visceral adiposity, promotes lipogenesis and ectopic lipid accumulation, and decreases insulin sensitivity in humans [30, 32, 3944] as well as rodents [30, 38, 4552]. Based on these various findings, it appears that excessive consumption of fructose contributes to NAFLD pathogenesis in two ways: 1) it promotes TG production via de novo lipogenesis resulting in hyperlipidemia; and 2) it contributes to inflammation resulting in insulin resistance, steatosis, hepatic inflammation and fibrosis [53].

The creosote bush – Larrea tridentate – which grows abundantly in the North American and Mexican deserts, has been used by tribes native to these areas in the treatment of a wide range of ailments, including kidney and gallbladder stones, infertility, chicken pox, tuberculosis, cancer, venereal disease, colds, pain, arthritis and inflammation [54]. Previous work from our laboratory ([55, 56] and references therein) and others [57, 58] has shown that nordihydroguaiaretic acid (NDGA), the main metabolite of Creosote Bush [54], has profound effects on the core components of metabolic syndrome, including lowering of blood glucose, free fatty acids (FFA) and triglyceride (TG) levels, and attenuating elevated blood pressure in several rodent models of dyslipidemia, as well as improving body weight (obesity), insulin resistance, diabetes and hypertension. In a recently published study [59] we provided evidence using control, high-fat diet fed C57BL/6 J pre-diabetes (diet-induced obesity [DIO]), ob/ob control and NDGA fed DIO and ob/ob mice that NDGA exerts its hypolipidemic actions, including amelioration of hepatic steatosis, predominantly by stimulating the activity of the nuclear hormone receptor, peroxisome proliferator activated α (PPARα or NR1C1), the master regulator of all three hepatic fatty acid oxidation systems [6067], which, in turn, improves dyslipidemia by promoting increased channeling of fatty acids towards their oxidation, and thus, restricting very low-density lipoprotein (VLDL)-TG production, storage, and secretion. We additionally observed that PPARα-independent pathways might also contribute to NDGA’s action to ameliorate hepatic steatosis.

To gain further insight into the molecular mechanisms underlying NDGA attenuation of dyslipidemia, including hypertriglyceridemia and hepatic steatosis, we utilized a microarray approach, which allowed us to observe the global effect of NDGA on lipid metabolism in three insulin sensitive tissues, liver, skeletal muscle and adipose tissues from high-fructose diet (HFrD)-induced hypertensive, hyperinsulinemic and hypertriglyceridemic rats. More specifically, the major goal of this study was to examine the effects of NDGA on expression of genes involved in lipid metabolism using HFrD fed rats to identify expression changes that might explain metabolic (i.e., insulin resistance, steatosis and hypertriglyceridemia) and histological (i.e., lipid droplet density) that are observed with NDGA treatment. Our results indicate that NDGA affects the expression of a large number of genes involved in fatty acid catabolism and synthesis in liver, muscle, and adipose tissue. In addition, based on these two affected pathways, several genes have been identified that may mediate the anti-hyperlipidemic actions of NDGA.

Results

Effect of chronic dietary NDGA treatment on physical and metabolic characteristics of high-fructose diet fed rats

We examined the effects of chronic dietary NDGA treatment on hypertriglyceridemia and hepatic steatosis, and profiled by microarray analysis the expression of enzymes and regulatory proteins involved in lipid metabolism of three insulin-sensitive tissues liver, skeletal muscle and adipose tissue. For these studies, the groups of rats were maintained on a control chow diet, HFrD or HFrD supplemented with 2.5 g NDGA/kg diet (HFrD-NDGA) (~94 mg/kg BW/24 h) for 16 weeks and, subsequently, liver, mixed gastrocnemius muscle and white adipose tissue samples were subjected to Gene Microarray Analysis. Serum samples collected at various time points were quantified for triglyceride, cholesterol, glucose and insulin levels. Chronic feeding of HFrD to male rats leads to hypertension, hyperinsulinemia, hypertriglyceridemia and inflammation [47, 56, 68].

There was no obvious gastrointestinal stress as manifest by diarrhea observed during the dietary treatment. Compared to the chow-fed control group, there was a significant reduction of body weight starting after 1 week in both HFrD and HFrD-NDGA groups (Fig. 1[a]). Furthermore, dietary consumption of NDGA resulted in much lower body weights as compared to either the HFrD or chow diet. There was no significant difference in food intake between the groups (Fig. 1[b]). These results suggest that suppression of body weight gain in HFrD-NDGA supplementation in the diet is not due to changes in food intake, but most likely due to increased energy expenditure and decreased adiposity. HFrD-induced increases in serum triglyceride levels were completely prevented in rats maintained on HFrD supplemented with NDGA (Fig. 2[a]). However, total cholesterol (Fig. 2[b]) and glucose were not different among the three groups except at weeks 9, 11 and 16. At week 9, total cholesterol levels were significantly higher following NDGA treatment (P < 0.01 Chow vs HFrD-NDGA; P < 0.05 HFrD vs HFrD-NDGA), whereas at 11 and 16 weeks, glucose levels were reduced in response to feeding HFrD (P < 0.05 Chow vs HFrD) and HFrD-NDGA (P < 0.05 Chow vs HFrD-NDGA), respectively (Fig. 2[b, c]). As shown in Fig. 2[d], circulating insulin levels were markedly increased with HFrD feeding, but decreased to almost control levels, although were significantly different than chow with the dietary administration of NDGA (P < 0.001).
Fig. 1

Effects of dietary administration of NDGA on body weight and diet consumption. a Body weight and b diet consumption in rats fed a chow diet (n = 8), HFrD (n = 12) or HFrD-NDGA (2.5 g/kg diet, n = 14)) for 8 weeks. Results are means ± SE. * p < 0.05, ** p < 0.01, *** p < 0.001 vs Chow, † p < 0.05, †† p < 0.01, ††† p < 0.001 vs HFrD

Fig. 2

Effects of dietary administration of NDGA on plasma metabolites. a triglyceride, b total cholesterol, c glucose, and d insulin. Rats were fed a chow diet, HFrD or HFrD-NDGA (2.5 g/kg diet) for 8 weeks. Results are means ± SE. * p < 0.05, ** p < 0.01, *** p < 0.001 vs Chow, † p < 0.05, †† p < 0.01, ††† p < 0.001 vs HFrD

Effect of chronic dietary NDGA treatment on hepatic lipid accumulation

Liver weights were significantly higher in both HFrD and HFrD-NDGA groups than controls, but no differences were noted between HFrD and HFrD-NDGA groups (Fig. 3[a]). Liver TG content increased approximately 6-fold in animals fed HFrD compared with control rats (P <0.001) and decreased by approximately 70 % in response to HFrD-NDGA feeding (P <0.001) (Fig. 3[b]). We also performed histological examinations on H&E stained liver sections prepared from chow, HFrD and HFrD-NDGA groups to assess the extent of hepatic steatosis. Hepatocytes from HFrD fed rats contained more lipids (white space) than control rats (Fig. 3[c]). In comparison, the extent of steatosis in liver tissue of rats fed HFrD-NDGA was reduced to the levels seen in chow-fed animals (Fig. 3[c]). We also calculated liver/body weight ratios. As can be seen in Fig. 4, HFrD + NDGA/body weight ratio was higher than HFrD/Body weight ratio. We speculate that this occurs because of increased hepatic glycogen accumulation, since livers of NDGA treated animals preferentially use fatty acids as an energy source. Similar results have been reported by Lee et al. [57] showing that high-fat diet (HFD) mice treated with NDGA had a higher liver body weight ratio than mice fed HFD alone.
Fig. 3

Effects of dietary administration of NDGA on liver weight, liver TG content and liver histology. a liver weight, b liver TG content, and c liver histology. Rats were fed a chow diet, HFrD or HFrD-NDGA (2.5 g/kg diet) for 8 weeks. Results are means ± SE. * p < 0.05, ** p < 0.01, *** p < 0.001 vs Chow, † p < 0.05, †† p < 0.01, ††† p < 0.001 vs HFrD

Fig. 4

Liver/body weight ratios for rats fed a Chow diet, HFrD or HFrD-NDGA. Liver/body weight ratios were calculated from the data presented in Figs. 1 and 3. Results are means ± SE. * p < 0.05, ** p < 0.01, ***p < 0.001 vs Chow, † p < 0.05, †† p < 0.01, ††† p < 0.001 vs HFrD

Principal component analysis of microarrays

Initially a principal component analysis (PCA) was performed to visualize patterns in the gene expression data and to highlight similarities and differences between the two diets (Chow vs HFrD) and NDGA treatment (HFrD vs HFrD-NDGA). Data are displayed in a simple Scatter Plot view of the first two principal components (PCs) (Fig. 5 [a-c]). In each case, all three gene clusters are well separated from each other, suggesting they are quite different.
Fig. 5

Principal component analysis (PCA) of gene expression profiles of white adipose tissue [a], liver [b] and mixed gastrocnemius muscle [c] samples from chow, HFrD and HFrD-NDGA fed animals

Effect of NDGA on expression of genes involved in lipid metabolism in liver, skeletal muscle and adipose tissue

To examine which components of hepatic metabolism were impacted by NDGA treatment in HFrD fed rats, we categorized genes involved in lipid metabolism into eight groups: fatty acid uptake and transport, acyl-CoA synthases, fatty acid oxidation, fatty acid synthesis (lipogenesis), TG synthesis and VLDL-TG assembly, cholesterol metabolism, lipid clearance, and key transcription factors involved in the regulation of genes of lipid metabolism. As can be seen from the results presented in Table 1, NDGA treatment robustly altered the genes of hepatic fatty acid oxidation and lipogenesis. Among the fourteen fatty acid oxidation genes analyzed, expression of six genes, including Cpt1b, Cpt2, Acox, Acadvl, Dci and Ehhadh, was significantly upregulated in response to NDGA treatment of high-fructose diet fed rats. The expression of Acadsb, however, was down-regulated following dietary administration of NDGA. Of the sixteen lipogenic enzyme genes examined, the expression levels of Gckr, Gck, Acly, Fasn, Scd1, Fads1, Fads2, Elovl2 and Elovl5 were down-regulated, whereas expression levels of Mlycd, Elovl4 and Elovl6 were up-regulated in response to dietary consumption of both HFrD and NDGA as compared to HFrD alone. On the other hand, feeding high-fructose diet alone increased the expression of a number of lipogenic genes, including Gckr, Gck, Pklr, Acyl, Fasn, Scd1, Fads1, Fads2, Elovl2, Elovl5, and Elovl6.
Table 1

Hepatic genes responsive to feeding of a high-fructose diet (HFrD) or HFrD supplemented with NDGA (HFrD-NDGA)

Gene symbol/GenBank accession/Gene ID

Entrez gene name

HFrD/Chow (Fold-change)

HFrD-NDGA/HFrD (Fold-change)

 

Fatty Acid Transport

  

Slc27a1

Acc: NM_053580.2

ID: 94172

Soluble carrier family 27 (fatty acid transporter), member 1 (FATP1)

0.817382

(p = 0.050249)

1.085686

(p = 0.548792)

Slc27a2

Acc: NM_031736.1

ID: 65192

Soluble carrier family 27 (fatty acid transporter), member 2 (FATP2)

1.276261↑

(p = 0.017602)

1.071673

(p = 0.458057)

 

Acyl-CoA Synthetases

  

Acsl1

Acc: NM_012820.1

ID: 25288

Acyl-CoA synthetase long-chain family member 1 (ACS, Acas, COAA, Facl2)

1.058003

(p = 0.59888)

1.286236↑

(p = 0.015343)

Acsl4

Acc: NM_053623.1

ID: 113976

Acyl-CoA synthetase long-chain family member 4 (ACS4, Facl4)

1.673512↑

(p = 0.000004)

0.697139↓

(p = 0.001224)

Acsm3

Acc: NM_033231.1

ID: 24763

Acyl-CoA synthetase medium-chain family member 3 (Sa, Sah)

0.458851↓

(p = 0.000004)

1.583156↑

(p = 0.000039)

Acss2

Acc: NM_001107793.1

ID: 311569

Acyl-CoA synthetase short chain family member 2 (Acss2)

1.640823↑

(p = 5.92E-09)

0.707869↓

(p = 0.000022)

 

Fatty Acid Oxidation

  

Cpt1a

Acc: NM_031559.2

ID: 25757

Carnitine palmitoyltransferase 1a, liver (CPT-1a)

2.093217↑

(p = 0.000002)

0.935127

(p = 0.569094)

Cpt1b

Acc: NM_013200.1

ID: 25756

Carnitine palmitoyltransferase 1b, muscle (CPT-1B, M-CPT1)

0.955041

(p = 0.714963)

4.901597↑

(p = 1.32E-23)

Cpt1c

Acc: NM_001034925.2

ID: 308579

Carnitine palmitoyltransferase 1c (CPT 1C, CPT1-B, CPTI-B)

0.786901

(p = 0.063481)

0.809912

(p = 0.13046)

Cpt2

Acc: NM_012930.1

ID: 25413

Carnitine palmitoyltransferase 2 (CPTII)

1.119695

(p = 0.344743)

2.583082↑

(p = 1.88E-16)

Acox1

Acc: NM_017340.2

ID: 506811

Acyl-CoA oxidase, palmitoyl (Rat ACOA1)

1.116564

(p = 0.176539)

3.27028↑

(p = 5.20E-32)

Acadl

Acc: NM_012819.1

ID: 25287

Acyl-CoA dehydrogenase, long chain (ACOADA, LCAD)

1.156082

(p = 0.178078)

1.023617

(p = 0.843391)

Acadm

Acc: NM_016986.2

ID: 24158

Acyl-CoA dehydrogenase, C-4 to C-12 straight chain (MCAD)

0.871033

(p = 0.206145)

1.171654

(p = 0.099023)

Acads

Acc: NM_022512.1

ID: 64304

Acyl-Coa dehydrogenase, C-2 to C-3 short chain (Scad)

1.125432

(p = 0.554859)

0.919627

(p = 0.563538)

Acadsb

Acc: NM_013084.1

ID: 25618

Acyl-CoA dehydrogenase, short/branched chain

1.060392

(p = 0.645381)

0.700742↓

(p = 0.030057)

Acadvl

Acc: NM_012891.1

ID: 25363

Acyl-CoA dehydrogenase very long chain (VLCAD)

1.034174

(p = 0.763361)

1.322826↑

(p = 0.003236)

Eci1

Acc: NM_017306.4

ID: 29740

Enoyl-CoA delta isomerase 1(Deci)

0.991668

(p = 0.91246)

2.461649↑

(p = 1.48E-11)

Echs1

Acc: NM_078623.2

ID: 140547

Enoy-CoA hydratase, short chain 1, mitochondrial

1.001718

(p = 0.984367)

0.982888

(p = 0.872986)

Ehhadh

Acc: NM_133606.1

ID: 171142

Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase

1.159127

(p = 0.181858)

5.837078↑

(p = 2.67E-36)

Eci2

Acc: NM_001006966.1

ID:291075

Enoyl-CoA delta isomerase 2 (Peci)

1.109171

(p = 0.294883)

1.04819

(p = 0.563012)

 

Fatty Acid Synthesis/ De Novo Lipogenesis

  

Gckr

Acc: NM_013120.2

ID: 25658

Glucokinase (hexokinase 4) regulator (GLRE)

1.225835↑

(p = 0.00735)

0.842312↓

(p = 0.029236)

Gck

Acc: NM_012565.1

ID: 24385

Glukokinase (GLUKA, RNGK2)

1.954322↑

(p = 2.09E-18)

0.6409↓

(p = 9.91E-08)

Pklr

Acc: NM_012624.3

ID: 24651

Pyruvate kinase, liver and RBC

(PK1, PKL, Pklg)

2.101247↑

(p = 0.013312)

0.763246

(p = 0.331269)

Acly

Acc: NM_016987.2

NM_001111095.1

ID: 24159

ATP citrate lyase (ACL, Clatp)

3.860112↑

(p = 8.66E-38)

0.669940↓

(p = 0.000006)

Fasn

Acc: NM_01332.1

ID: 50761

Fatty acid synthase

8.556156↑

(p = 00E + 00)

0.448329↓

(p = 2.08E-16)

Me1

Acc: NM_012600.2

ID: 24552

Malic enzyme 1, NADP(+)-dependent, cytosolic (MOD1)

8.437617↑

(p = 2.81E-20)

1.132866

(p = 0.447740)

Me2

Acc: NM_001111095.1

ID: 307270

Malic enzyme 2, NAD(+)-dependent, mitochondrial

Scd1

Acc: NM_139192.2

ID: 246074

Stearyol-Coenzyme A desaturase 1

9.689369↑

(p = 1.82E-38)

0.563616↓

(p = 3.64E-11)

Elovl1

Acc: NM_001044275.1

ID: 67953.2

ELOVL fatty acid elongase 1

0.996626

(p = 0.968014)

and

0.943940

(p = 0.460163)

0.956685

(p = 0.573719)

and

1.033276

(p = 0.664855)

Elovl2

Acc: NM_001109118.1

ID: 498728

ELOVL fatty acid elongase 2

2.461290↑

(p = 6.36E-19)

0.498430↓

(p = 3.66E-11)

Elovl4

Acc: NM_001191796.1 XM_001062735.2

ID: 315851

ELOVL fatty acid elongase 4

0.823072

(p = 0.428065)

1.658203↑

(p = 0.022936)

Elovl5

Acc: NM_134382.1

ID: 171400

ELOVL fatty acid elongase 5 (rELO1)

1.898944↑

(p = 1.23E-11)

0.416035↓

(p = 1.73E-17)

Elovl6

Acc: NM_134383.2

ID: 171402

ELOVL fatty acid elongase 6 (Lce2, rELO2)

9.009938↑

(p = 0.00E + 00)

and

2.808326↑

(p = 5.04E-11)

1.516732↑

(p = 6.34E-09)

and

1.466229↑

(p = 0.000012)

Fads1

Acc: NM_053445.2

ID: 84575

Fatty acid desaturase 1

1.241893↑

(p = 0.044164)

0.760081↓ (p = 0.006978)

Fads2

Acc: NM_031344.2

ID: 83512

Fatty acid desaturase 2 (Fadsd6)

2.161421↑ (p = 8.64E-12)

0.699797↓ (p = 0.000734)

Mlcyd

Acc: NM_053477.1

ID: 85239

Malonyl-CoA decarboxylase

1.018118

(p = 0.862908)

1.421141↑

(p = 0.000017)

 

Triglyceride (TG) Synthesis/VLDL-TG Assembly

  

Agpat1

Acc: NM_212458.1

ID: 406165

1-Acylglycerol-3-phosphate O-acyltransferase 1

0.695809↓

(p = 0.00083)

0.906865

(p = 0.595394)

Agpat2

Acc: NM_001107821.1

ID: 311821

1-Acylglycerol-3-phosphate O-acyltransferase 2

0.846901

(p = 0.109629)

1.048686

(p = 0.622341)

Agpat3

Acc: NM_001106378.1

ID: 311821

1-Acylglycerol-3-phosphate O-acyltransferase 3

0.848841

(p = 0.540663)

0.895847

(p = 0.800248)

Agpat6

Acc: NM_001047849.1

ID: 305166

1-Acylglycerol-3-phosphate O-acyltransferase 6 (RGD1310520)

1.024470

(p = 0.740343)

0.977072

(p = 0.773786)

Agpat9

Acc: NM_001025670.1

ID: 305166

1-Acylglycerol-3-phosphate O-acyltransferase 9

Mogat1

Acc: NM_001108803.1

ID: 363261

Monoacylglycerol O-acyltransferase 1

0.682029

(p = 0.154868)

1.75896↑

(p = 0.030197)

Dgat1

Acc: NM_053437.1

ID: 84497

Diacylglycerol O-acyltransferase 1 (ARAT, Dgat)

1.222808↑

(p = 0.030522)

1.067215

(p = 0.527579)

Dgat2

Acc: NM_001012345.1

ID: 252900

Diacylglycerol O-acyltransferase 2 (ARAT)

1.171782

(p = 0.67572)

0.664628↓

(p = 0.000124)

Arf3

Acc: NM_080904.2

ID: 140940

ADP-ribosylation factor 3 (AC1-253) Cholesterol Synthesis/Metabolism

1.046754

(p = 0.67572)

0.743228↓

(p = 0.001530)

 

Cholesterol Synthesis/Metabolism

  

Acat2

Acc: NM_001006995.1

ID: 308100

Acetyl-CoA acetyltransferase 2 (Acat3, Ab2-076)

0.944516

(p = 0.461984)

0.957373

(p = 0.56688)

Hmgcr

Acc: NM_013134.2

ID: 25675

3-Hydroxy-3-methylglutaryl-CoA reductase (3H3M)

1.438208↑

(p = 0.000036)

0.735862↓

(p = 0.002838)

Insig 1

Acc: NM_022392.1

ID: 64194

Insulin induced gene 1

2.844270↑

(p = 9.18E-16)

0.542157↓

(p = 0.000001)

Insig 2

Acc: NM_178091.4

ID: 288985

Insulin induced gene 2

0.831160↓

(p = 0.044277)

0.630641↓

(p = 8.36E-09)

Ldlr

Acc: NM_175762.2

ID: 300438

Low density lipoprotein receptor (LDLRA)

1.439569↑

(p = 0.003984)

0.840219

(p = 0.137488)

Mvk

Acc: NM_031063.1

ID: 81727

Mevalonate kinase (Lrbp)

0.663626↓

(p = 0.000016)

1.149403

(p = 0.234165)

Scap

Acc: NM_001100966.1

ID: 301024

SREBF chaperone Proteins Involved in Lipid Clearance

1.171144↑

(p = 0.035192)

0.995421

(p = 0.941247)

 

Proteins Involved in Lipid Clearance

  

Abca4

Acc: NM_00110772.1

ID: 310836

ATP-binding cassette, subfamily A (ABC1), member 4 (ABCR)

Abcb4

Acc: NM_012690.1

ID: 24891

ATP-binding cassette, subfamily B (MDR/TAP), member 4 (Mdr2, Pgy3)

0.489385↓

(p = 3.69E-12)

1.099759

(p = 0.27820)

Abcb11

Acc: NM_031760.1

ID: 83569

ATP-binding cassette, subfamily B (MDR/TAP), member 11 (Bsep, Spgp)

0.752953↓

(p = 0.001332)

1.158787

(p = 0.07294)

Abcc3

Acc: NM_080581.1

ID: 140668

ATP-binding cassette, subfamily C (CFTR/MRP), member 3 (Mlp2, Mrp3)

0.813337

(p = 0.08045)

2.659410↑

(p = 7.16E-11)

Abcc6

Acc: NM_031013.1

ID: 81642

ATP-binding cassette, subfamily C (CFTR/MRP), member 6 (Mrp6)

1.085723

(p = 0.31384)

0.717441↓

(p = 0.00001)

Abcd1

Acc: NM_001108821.1

ID: 363516

ATP-binding cassette, subfamily D (ALD), member 3 (RGD1562128)

1.087157

(p = 0.468224)

0.943107

(p = 0.56163)

Abcd3

Acc: NM_012804.1

ID: 25270

ATP-binging cassette, subfamily D (ALD), member 3 (PMP70, Pxmp1)

1.178867↑

(p = 0.035741)

2.15542↑

(p = 2.62E-16)

Abcg2

Acc: NM_181381.2

ID: 312382

ATP-binding cassette, subfamily G (WHITE), member 2 (BCRP1)

1.940981↑

(p = 0.000000)

1.140117

(p = 0.258891)

Abcg5

Acc: NM_053754.2

ID: 114628

ATP-binding cassette, subfamily G (WHITE), member 5

0.297237↓

(p = 5.23E-28)

3.499936↑

(p = 5.81E-28)

Apoa4

Acc: NM_012737.1

ID: 25080

Apolipoprotein A-IV (Apo-AIV, ApoA-IV, ApoAIV)

1.316723↑

(p = 0.025675)

0.447885↓

(p = 1.8E-10)

Apob

Acc: NM_019287.2

ID: 54225

Apolipoprotein B (Aa1064, AC1-060, Apo B-100, ApoB-100, ApoB-48)

0.895361

(p = 0.277000)

1.130493

(p = 0.142599)

Apoc2

Acc: NM_001085352.1

ID: 292697

Apolipoprotein C-II (RGD1560725)

0.981675

(p = 0.864333)

0.941418

(p = 0.591544)

Apoc3

Acc: NM_012501.1

ID: 24207

Apolipoprotein C-III (ApoC-III, apo-CIII)

0.887282

(p = 0.221273)

1.133806

(p = 0.221176)

Apoe

Acc: NM_138828.2

ID: 25728

Apolipoprotein E (APOEA)

0.953286

(p = 0.543392)

0.968783

(p = 0.800654)

Apof

Acc: NM_001024351.1

ID: 500761

Apolipoprotein F

1.053397

(p = 0.630710)

0.558207↓

(p = 0.000001)

Lpl

Acc: NM_012498.2

ID: 24539

Lipoprotein lipase

1.300129↑

(p = 0.024577)

3.799195↑

(p = 1.34E-16)

Vldlr

Acc: NM_013155.2

ID: 25696

Very low density lipoprotein receptor

0.993145

(p = 0.973839)

Or

1.103786

(p = 0.800081)

1.615341↑

(p = 0.012976)

Or

1.454645

(p = 0.304421)

Ppt1

Acc: NM_022502.2

ID: 29411

Palmitoyl-protein thioesterase 1 (Ppt)

1.055246

(p = 0.5199114)

0.882921

(p = 0.192733)

 

Central Metabolic Regulators (Lipid Transcription Factors)

  

Foxa1

Acc: NM_012742.1

ID: 25098

Forkhead box A1

1.489049↑

(p = 0.001314)

Or

1.271372↑

(p = 037977)

0.831777

(p = 0.136951)

Or

0.645434↓

(p = 0.000052)

Hnf4a

Acc: NM_022180.1

ID: 25735

Hepatocyte nuclear factor 4, alpha (Hnf4alpha, Hnf4a)

0.912061

(p = 0.377142)

1.357585↑

(p = 0.003965)

Mlxipl

Acc: NM_133552.1

ID: 171078

MLX interacting protein-like (ChREBP, WS-bHLH, Wbscr14, bHLHd14)

1.976840↑

(p = 1.9E-15)

0.724559↓

(p = 0.000044)

Nr1h3

Acc: NM_031627.2

ID: 58852

Nuclear receptor subfamily 1, group H, member 3 (LXRalpha)

0.980054

(p = 0.831777)

1.208346↑

(p = 0.041273)

Ppara

Acc: NM_013196.1

ID: 25747

Peroxisome proliferator activated receptor alpha (PPAR)

1.009554

(p = 0.946257)

1.760026↑

(p = 0.000067)

Ppard

Acc: NM_013141.2

ID: 25682

Peroxisome proliferator activated receptor delta (Pparb)

0.843786

(p = 0.226207)

and

1.189417

(p = 0.204488)

0.753122

(p = 0.144411)

and

0.635361↓

(p = 0.029129

Pparg

Acc: NM_013124.3

NM_001145366.1

NM_001145367.1

ID: 25664

Peroxisome proliferator activated receptor gamma

1.010459

(p = 0.879959)

1.03214

(p = 0.742011)

Ppargc1a

Acc: NM_031347.1

ID: 83516

Peroxisome proliferator activated receptor gamma, coactivator 1 alpha(Ppargc1)

0.738155

(p = 0.120955)

Ppargc1b

Acc: NM_176075.2

ID: 291567

Peroxisome proliferator activated receptor, coactivator 1 beta (PGC1beta, Perc)

0.969931

(p = 0.815666)

1.534911↑

(p = 0.012486)

Srebf1

Acc: XM_213329.5

XM_001075680.2

ID: 78968

Sterol regulatory element binding transcription factor 1 (ADD-1, ADD1, SREBP-1, SREBP-1c, Srebp1)

1.604384↑

(p = 0.000000)

and

1.456690↑

(p = 0.001744)

0.8782

(p = 0.125948)

and

0.934259

(p = 0.479001)

Srebf2

Acc: NM_001033694.1

ID: 300095

Sterol regulatory element binding transcription factor 2 (SREBP-2, SREBP2-retired, Srebf2)

0.732025↓

(p = 0.000761)

1.071545

(p = 0.478687)

Xbp1

Acc: NM_001004210.1

ID: 289754

X-box binding protein 1 (HTF)

1.148942

(p = 0.076252)

0.807070↓

(p = 0.016697)

The expression of acyl-CoA synthetases, which channel fatty acids into different pathways of lipid metabolism, was differentially impacted by NDGA treatment; NDGA treatment increased Acsl1 and Acsm3 mRNA levels, but decreased Acsl4 and Acss2 levels (Table 1). Likewise, NDGA treatment differentially increased Abcc3, Abcd3, Abcg5, Lpl, and Vldr and decreased Abcc6, Apoa4, Apof, genes that participate in lipid clearance. Surprisingly, NDGA showed no significant effect on various genes involved in TG synthesis/assembly with the exception of Mogat1 (↑), Dgat2 (↓) and Arf3 (↓). Key transcription factors of hepatic lipid metabolism, such as Hnf4a, Ppara, Nr1h3 and Ppargc1b, showed enhanced expression, whereas Foxa1, Mlxipl, Srebf1, Ppard and Xbp1 expression was significantly reduced in HFrD-NDGA treated animals as compared to HFrD treated animals (Table 1).

Qualitatively similar to hepatic gene expression, data were obtained for the mixed gastrocnemius muscle, a representative of skeletal muscle types. Expression of fatty acid oxidation genes, Cpt1c, Acox1, Acadsb, Dci, and Ehhadh, was up-regulated, but the expression of Cpt1a, Cpt1b and Peci was down-regulated with NDGA treatment (Table 2). Four fatty acid synthesizing enzyme genes (Gckr, Gck, Fads1 and Fads2) were upregulated by NDGA treatment, but the expression of three genes, (Acly, Elovl1 and Elovl5) was down-regulated in response to NDGA treatment. No NDGA effect was noted on the expression levels of key lipogenic enzymes, Fasn and Scd1. The expression levels of fatty acid transport proteins Slc27a2 and Slc27a1 and acyl-CoA synthetases Acss2 and Acsl1 were up-regulated and down-regulated, respectively, as a result of NDGA treatment. The key TG synthesizing genes Agpat1, Dgat1 and Dgat2 were increased in the HFrD-NDGA treated group compared to HFrD alone, but the expression levels of other genes, Agpat2, Mogat1 and Arf3, were reduced with NDGA treatment. The expression levels of some genes involved in lipid clearance, Abcb4, Abcb11, Apob, Apoc2, Apoc3 and Vldlr, were significantly upregulated, while levels of Abcc3, Apoe and Lpl were downregulated in response to NDGA treatment of HFrD fed rats. Interestingly, NDGA treatment increased the expression of both transcription factors involved in fatty acid oxidation (Ppara and Ppard) and fatty acid synthesis (Nr1h3, Srebf1 and Xbp1) (Table 2).
Table 2

Skeletal muscle genes responsive to feeding of a high-fructose diet (HFrD) or HFrD supplemented with NDGA (HFrD-NDGA)

Gene symbol/GenBank accession/Gene ID

Entrez gene name

HFrD/Chow (Fold-change)

HFrD-NDGA/HFrD (Fold-change)

 

Fatty Acid Transport

  

Slc27a1

Acc: NM_053580.2

ID: 94172

Soluble carrier family 27 (fatty acid transporter), member 1 (FATP1)

1.163926

(p = 0.067083)

0.603296↓

(p = 0.000002)

Slc27a2

Acc: NM_031736.1

ID: 65192

Soluble carrier family 27 (fatty acid transporter), member 2 (FATP2)

0.8357

(p = 0.727766)

6.826838↑

(p = 7.06E-28)

 

Acyl-CoA Synthetases

  

Acsl1

Acc: NM_012820.1

ID: 25288

Acyl-CoA synthetase long-chain family member 1 (ACS, Acas, COAA, Facl2)

0.929637

(p = 0.400503)

0.818346↓

(p = 0.04231)

Acsl4

Acc: NM_053623.1

ID: 113976

Acyl-CoA synthetase long-chain family member 4 (ACS4, Facl4)

1.060922

(p = 0.54153)

1.353734

(p = 0.125592)

Acsm3

Acc: NM_033231.1

ID: 24763

Acyl-CoA synthetase medium-chain family member 3 (Sa, Sah)

1.134565

(p = 0.63539)

1.518789

(p = 0.055276)

Acss2

Acc: NM_001107793.1

ID: 311569

Acyl-CoA synthetase short chain family member 2 (Acss2)

1.011241

(p = 0.898282)

1.280275↑

(p = 0.002825)

 

Fatty Acid Oxidation

  

Cpt1a

Acc: NM_031559.2

ID: 25757

Carnitine palmitoyltransferase 1a, liver (CPT-1a)

1.067497

(p = 0.448414)

0.449902↓

(p = 5.12E-08)

Cpt1b

Acc: NM_013200.1

ID: 25756

Carnitine palmitoyltransferase 1b, muscle (CPT-1B, M-CPT1)

0.828098↓

(p = 0.041576)

0.715237↓

(p = 0.000001)

Cpt1c

Acc: NM_001034925.2

ID: 308579

Carnitine palmitoyltransferase 1c (CPT 1C, CPT1-B, CPTI-B)

1.086711

(p = 0.58947)

1.392775↑

(p = 0.007650)

Cpt2

Acc: NM_012930.1

ID: 25413

Carnitine palmitoyltransferase 2 (CPTII)

1.095366

(p = 0.319692)

0.935788

(p = 0.459054)

Acox1

Acc: NM_017340.2

ID: 506811

Acyl-CoA oxidase, palmitoyl (RATACOA1)

0.942485

(p = 0.405327)

1.239981↑

(p = 0.026649)

Acadl

Acc: NM_012819.1

ID: 25287

Acyl-CoA dehydrogenase, long chain (ACOADA, LCAD)

1.038506

(p = 0.607105)

0.897447

(p = 0.286828)

Acadm

Acc: NM_016986.2

ID: 24158

Acyl-CoA dehydrogenase, C-4 to C-12 straight chain (MCAD)

1.018954

(p = 0.786051)

1.120494

(p = 0.185916)

Acads

Acc: NM_022512.1

ID: 64304

Acyl-Coa dehydrogenase, C-2 to C-3 short chain (Scad)

0.947987

(p = 0.686716)

1.163831

(p = 0.106741)

Acadsb

Acc: NM_013084.1

ID: 25618

Acyl-CoA dehydrogenase, short/branched chain

0.767644

(p = 0.056663)

1.578611↑

(p = 0.000470)

Acadvl

Acc: NM_012891.1

ID: 25363

Acyl-CoA dehydrogenase very long chain (VLCAD)

1.023041

(p = 0.81081)

1.104065

(p = 0.242381)

Eci1

Acc: NM_017306.4

ID: 29740

Enoyl-CoA delta isomerase 1(Deci)

1.028304

(p = 0.734099)

1.203436↑

(p = 0.11201)

Echs1

Acc: NM_078623.2

ID: 140547

Enoy-CoA hydratase, short chain 1,

mitochondrial

0.890438

(p = 0.269622)

0.970797

(p = 0.801854)

Ehhadh

Acc: NM_133606.1

ID: 171142

Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase

1.255433↑

(p = 0.004941)

4.521567↑

(p = 1.81E-20)

Eci2

Acc: NM_001006966.1

ID:291075

Enoyl-CoA delta isomerase 2 (Peci)

0.899414

(p = 0.120824)

0.74287↓

(p = 0.000344)

 

Fatty Acid Synthesis/ De Novo Lipogenesis

  

Gckr

Acc: NM_013120.2

ID: 25658

Glucokinase (hexokinase 4) regulator (GLRE)

1.07709

(p = 0.694603)

2.031414↑

(p = 0.00004)

Gck

Acc: NM_012565.1

ID: 24385

Glukokinase (GLUKA, RNGK2)

0.959106

(p = 0.801909)

1.706245↑

(p = 0.000131)

Pklr

Acc: NM_012624.3

ID: 24651

Pyruvate kinase, liver and RBC (PK1, PKL, Pklg)

1.013481

(p = 0.932088)

1.252908

(p = 0.073772)

Acly

Acc: NM_016987.2

NM_001111095.1

ID: 24159

ATP citrate lyase (ACL, Clatp)

0.998949

(p = 0.98697)

0.737265↓

(p = 0.000026)

Fasn

Acc: NM_01332.1

ID: 50761

Fatty acid synthase

0.706952↓

(p = 0.000244)

0.930935

(p = 0.545657)

Me1

Acc: NM_012600.2

ID: 24552

Malic enzyme 1, NADP(+)-dependent, cytosolic (MOD1)

0.822072

(p = 0.082114)

1.1122701

(p = 0.365453)

Me2

Acc: NM_001111095.1

ID: 307270

Malic enzyme 2, NAD(+)-dependent, mitochondrial

Scd1

Acc: NM_139192.2

ID: 246074

Stearyol-Coenzyme A desaturase 1

1.31285↑

(p = 0.002357)

0.761013

(p = 0.065913)

Elovl1

Acc: NM_001044275.1

ID: 67953.2

ELOVL fatty acid elongase 1

1.011133

(p = 0.897404)

and

0.943484

(p = 0.539378)

0.639064↓

(p = 5.49E-08)

and

0.584865↓

(p = 0.000002)

Elovl2

Acc: NM_001109118.1

ID: 498728

ELOVL fatty acid elongase 2

2.709103

(p = 0.626956)

1.216575

(p = 0.73873)

Elovl4

Acc: NM_001191796.1

XM_001062735.2

ID: 315851

ELOVL fatty acid elongase 4

0.831144

(p = 0.17275)

0.905935

(p = 0.619544)

Elovl5

Acc: NM_134382.1

ID: 171400

ELOVL fatty acid elongase 5 (rELO1)

0.732669↓

(p = 0.000051)

0.768796↓

(p = 0.002744)

Elovl6

Acc: NM_134383.2

ID: 171402

ELOVL fatty acid elongase 6

(Lce2, rELO2)

1.034949

(p = 0.742391)

and

0.974533

(p = 0.82477)

0.993401

(p = 0.969926)

and

1.246617

(p = 0.381630)

Fads1

Acc: NM_053445.2

ID: 84575

Fatty acid desaturase 1

1.241893↑

(p = 0.044164)

0.760080↓

(p = 0.006978)

Fads2

Acc: NM_031344.2

ID: 83512

Fatty acid desaturase 2 (Fadsd6)

2.161421↑

(p = 8.64E-12)

0.699797↓

(p = 0.000734)

Mlcyd

Acc: NM_053477.1

ID: 85239

Malonyl-CoA decarboxylase

1.050798

(p = 0.506797)

0.988309

(p = 0.909295)

 

Triglyceride (TG) Synthesis/VLDL-TG Assembly

  

Agpat1

Acc: NM_212458.1

ID: 406165

1-Acylglycerol-3-phosphate O-acyltransferase 1

0.992486

(p = 0.954388)

1.306654↑

(p = 0.038298)

Agpat2

Acc: NM_001107821.1

ID: 311821

1-Acylglycerol-3-phosphate O-acyltransferase 2

1.090764

(p = 0.284579)

0.732075↓

(p = 0.001118)

Agpat3

Acc: NM_001106378.1

ID: 311821

1-Acylglycerol-3-phosphate O-acyltransferase 3

0.943450

(p = 0.5559170)

0.954861

(p = 0.819498)

Agpat6

Acc: NM_001047849.1

ID: 305166

1-Acylglycerol-3-phosphate O-acyltransferase 6 (RGD1310520)

0.976834

(p = 0.754188)

1.114009

(p = 0.256854)

Agpat9

Acc: 001025670.1

ID: 305166

1-Acylglycerol-3-phosphate O-acyltransferase 9

0.753988↓

(p = 0.002922)

0.791921

(p = 0.185478)

Mogat1

Acc: NM_001108803.1

ID: 363261

Monoacylglycerol O-acyltransferase

1

0.875509

(p = 0.391965)

0.592216↓

(p = 0.000892)

Dgat1

Acc: NM_053437.1

ID: 84497

Diacylglycerol O-acyltransferase 1 (ARAT, Dgat)

0.928218

(p = 0.359588)

1.485906↑

(p = 0.000110)

Dgat2

Acc: NM_001012345.1

ID: 252900

Diacylglycerol O-acyltransferase 2 (ARAT)

0.911253

(p = 0.262778)

1.451837↑

(p = 0.000067)

Arf3

Acc: NM_080904.2

ID: 140940

ADP-ribosylation factor 3 (AC1-253)

1.119282

(p = 0.211709)

0.530910↓

(p = 8.33E-12)

 

Cholesterol Synthesis/Metabolism

  

Acat2

Acc: NM_001006995.1

ID: 308100

Acetyl-CoA acetyltransferase 2 (Acat3, Ab2-076)

0.952536

(p = 0.440569)

0.989649

(p = 0.940796)

Hmgcr

Acc: NM_013134.2

ID: 25675

3-Hydroxy-3-methylglutaryl-CoA reductase (3H3M)

1.070248

(p = 0.412922)

0.663322↓

(p = 0.008738)

Insig 1

Acc: NM_022392.1

ID: 64194

Insulin induced gene 1

1.242984↑

(p = 0.031151)

1.549161↑

(p = 0.003666)

Insig 2

Acc: NM_178091.4

ID: 288985

Insulin induced gene 2

0.864261

(p = 0.073905)

1.265492

(p = 0.070329)

Ldlr

Acc: NM_175762.2

ID: 300438

Low density lipoprotein receptor

(LDLRA)

0.994617

(p = 0.974217)

0.996123

(p = 0.972744)

Mvk

Acc: NM_031063.1

ID: 81727

Mevalonate kinase (Lrbp)

1.014383

(p = 0.892250)

1.129775

(p = 0.245258)

Npc1

Acc:

NM_001002025.11

ID: 266732

Niemann-Pick disease, type C1

(Cdig2)

1.002647

(p = 998400)

0.806589

(p = 0.314930)

 

Proteins Involved in Lipid Clearance

  

Abca4

Acc: NM_00110772.1

ID: 310836

ATP-binding cassette, subfamily A (ABC1), member 4 (ABCR)

Abcb4

Acc: NM_012690.1

ID: 24891

ATP-binding cassette, subfamily B (MDR/TAP), member 4 (Mdr2, Pgy3)

1.001665

(p = 0.990316)

1.352659↑

(p = 0.002415)

Abcb11

Acc: NM_031760.1

ID: 83569

ATP-binding cassette, subfamily B (MDR/TAP), member 11 (Bsep, Spgp)

0.976717

(p = 0.887315)

2.314507↑

(p = 0.000044)

Abcc3

Acc: NM_080581.1

ID: 140668

ATP-binding cassette, subfamily C (CFTR/MRP), member 3 (Mlp2, Mrp3)

1.13094

(p = 0.112959)

0.554283↓

(p = 3.47E-08)

Abcc6

Acc: NM_031013.1

ID: 81642

ATP-binding cassette, subfamily C (CFTR/MRP), member 6 (Mrp6)

1.016698

(p = 0.931493)

2.173900↑

(p = 0.000012)

Abcd1

Acc: NM_001108821.1

ID: 363516

ATP-binding cassette, subfamily D (ALD), member 3 (RGD1562128)

0.966064

(p = 0.685132)

1.009964

(p = 0.42331)

Abcd3

Acc: NM_012804.1

ID: 25270

ATP-binging cassette, subfamily D (ALD), member 3 (PMP70, Pxmp1)

1.071230

(p = 0.315252)

1.178834

(p = 0.074443)

Abcg2

Acc: NM_181381.2

ID: 312382

ATP-binding cassette, subfamily G (WHITE), member 2 (BCRP1)

0.940064

(p = 0.737683)

Abcg5

Acc: NM_053754.2

ID: 114628

ATP-binding cassette, subfamily G (WHITE), member 5

0.980266

(p = 0.916333)

0.810473

(p = 506217)

Apoa4

Acc: NM_012737.1

ID: 25080

Apolipoprotein A-IV (Apo-AIV, ApoA-IV, ApoAIV)

0.886124

(p = 637386)

1.397129

(p = 0.121159)

Apob

Acc: NM_019287.2

ID: 54225

Apolipoprotein B (Aa1064, AC1-060, Apo B-100, ApoB-100, ApoB-48)

0.726099

(p = 0.275237)

5.457586↑

(p = 5.48E-13)

Apoc2

Acc: NM_001085352.1

ID: 292697

Apolipoprotein C-II (RGD1560725)

0.935620

(p = 0.636398)

3.570020↑

(p = 2.22E-17)

Apoc3

Acc: NM_012501.1

ID: 24207

Apolipoprotein C-III (ApoC-III, apo-CIII)

0.912894

(p = 0.302897)

8.022169↑

(p = 6.3E-25)

Apoe

Acc: NM_138828.2

ID: 25728

Apolipoprotein E (APOEA)

1.177138

(p = 0.066475)

0.419997↓

(p = 1.01E-13)

Apof

Acc: NM_001024351.1

ID: 500761

Apolipoprotein F

Lpl

Acc: NM_012498.2

ID: 24539

Lipoprotein lipase

0.985218

(p = 0.852647)

0.543580↓

(p = 4.93E-12)

Vldlr

Acc: NM_013155.2

ID: 25696

Very low density lipoprotein receptor

1.062438

(p = 0.461893)

Or

0.888362

(p = 0.228697)

1.091786

(p = 0.205328)

Or

1.200139↑

(p = 0.030468)

Ppt1

Acc: NM_022502.2

ID: 29411

Palmitoyl-protein thioesterase 1 (Ppt)

0.959614

(p = 0.555592)

0.505612↓

(p = 5.61E-15)

(p = 0.192733)

 

Central Metabolic Regulators (Lipid Transcription Factors)

  

Foxa1

Acc: NM_012742.1

ID: 25098

Forkhead box A1

0.861648

(p = 0.59303)

0.790538

(p = 0.286379)

Hnf4a

Acc: NM_022180.1

ID: 25735

Hepatocyte nuclear factor 4, alpha (Hnf4alpha, Hnf4a)

0.969862

(p = 0.899345)

0.897382

(p = 0.784789)

Mlxipl

Acc: NM_133552.1

ID: 171078

MLX interacting protein-like (ChREBP, WS-bHLH, Wbscr14, bHLHd14)

0.644817↓

(p = 1.16E-08)

0.923704

(p = 0.439391)

Nr1h3

Acc: NM_031627.2

ID: 58852

Nuclear receptor subfamily 1, group H, member 3 (LXRalpha)

1.002888

(p = 0.964985)

1.708129↑

(p = 0.000001)

Ppara

Acc: NM_013196.1

ID: 25747

Peroxisome proliferator activated receptor alpha (PPAR)

0.897809

(p = 0.394852)

2.537218↑

(p = 0.000000)

Ppard

Acc: NM_013141.2

ID: 25682

Peroxisome proliferator activated receptor delta (Pparb)

1.000165

(p = 0.998956)

and

0.991657

(p = 0.964720)

1.428902↑

(p = 0.005855)

and

1.167184

(p = 0.271325)

Pparg

Acc: NM_013124.3 NM_001145366.1

NM_001145367.1

ID: 25664

Peroxisome proliferator activated receptor gamma

0.801471↓

(p = 0.003078)

0.924624

(p = 0.447736)

Ppargc1a

Acc: NM_031347.1

ID: 83516

Peroxisome proliferator activated receptor gamma, coactivator 1 alpha (Ppargc1)

0.719326

(p = 0.192474)

1.479666

(p = 0.067544)

Ppargc1b

Acc: NM_176075.2

ID: 291567

Peroxisome proliferator activated receptor, coactivator 1 beta (PGC1beta, Perc)

1.020089

(p = 0.82730)

0.633941↓

(p = 0.001608)

Srebf1

Acc: XM_213329.5

XM_001075680.2

ID: 78968

Sterol regulatory element binding transcription factor 1 (ADD-1, ADD1, SREBP-1, SREBP-1c, Srebp1)

0.986205

(p = 0.859100)

and

1.018349

(p = 0.853102)

1.837534↑

(p = 9.10E-08)

and

1.865578↑

(p = 0.000003)

Srebf2

Acc: NM_001033694.1

ID: 300095

Sterol regulatory element binding transcription factor 2 (SREBP-2, SREBP2-retired, Srebf2)

1.028776

(p = 0.707159)

0.82597

(p = 0.471771)

Xbp1

Acc: NM_001004210.1

ID: 289754

X-box binding protein 1 (HTF)

1.055655

(p = 0.434625)

1.317409↑

(p = 0.000651)

Compared to liver and skeletal muscle, relatively less effect of NDGA was detected on lipid metabolizing genes in white adipose tissue (Table 3). The adipose expression of fatty acid transporter Slc27a1 was significantly reduced by high-fructose feeding, whereas its levels were markedly increased in HFrD rats treated with NDGA. Likewise, consumption of the high-fructose diet led to down-regulation of the majority of fatty acid oxidation genes except Acox1, whereas NDGA treatment increased expression of only Acadsb and Acadvl (Table 3). In addition, HFrD feeding increased the expression of lipogenic genes such as Gck, Pklr, Acly, and Scd1, but reduced the levels of Elovl1. Simultaneous HFrD and NDGA feeding decreased the expression of several lipogenic genes, e.g., Gck, Pklr, Scd1, and Fads1, but increased the expression Elovl1, Elovl5 and Elovl6. The expression of a number of genes involved in TG synthesis, such as Agpat1, Agpat3, Agpat6, Agpat9, Dgat1 and Arf3, were reciprocally regulated by HFrD feeding and HFrD-NDGA treatment. Both high-fructose feeding and combined high-fructose diet and NDGA treatment markedly altered the expression of key genes involved in lipid clearance, e.g., Apo4, Apoc2, Apoc3, Apoe, VLDLR and Lpl (Table 3). Among the lipid transcription factors, the expression of Ppara, Srebf1, and Nr1h3 was increased following NDGA treatment, whereas high-fructose feeding alone decreased the expression of Ppargc1b and Srebf1 genes. In contrast, HFrD feeding increased the expression of Pparg1a.
Table 3

Adipose tissue genes responsive to feeding of a high-fructose diet (HFrD) or HFrD supplemented with NDGA (HFrD-NDGA)

Gene symbol/GenBank accession/Gene ID

Entrez gene name

HFrD/Chow

(Fold-change)

HFrD-NDGA/HFrD

(Fold-change)

 

Fatty Acid Transport

  

Slc27a1

Acc: NM_053580.2

ID: 94172

Soluble carrier family 27 (fatty acid transporter), member 1 (FATP1)

0.626371↓

(p = 0.000005)

1.243585↑

(p = 0.035818)

Slc27a2

Acc: NM_031736.1

ID: 65192

Soluble carrier family 27 (fatty acid transporter), member 2 (FATP2)

0.843521

(p = 0.704995)

 

Acyl-CoA Synthetases

  

Acsl1

Acc: NM_012820.1

ID: 25288

Acyl-CoA synthetase long-chain family member 1 (ACS, Acas, COAA, Facl2)

0.871766

(p = 0.143945)

1.022277

(p = 0.780026)

Acsl4

Acc: NM_053623.1

ID: 113976

Acyl-CoA synthetase long-chain family member 4 (ACS4, Facl4)

0.878305

(p = 0.54153)

0.964436

(p = 0.62090)

Acsm3

Acc: NM_033231.1

ID: 24763

Acyl-CoA synthetase medium-chain family member 3 (Sa, Sah)

0.987186

(p = 0.961215)

0.805024

(p = 0.413656)

Acss2

Acc: NM_001107793.1

ID: 311569

Acyl-CoA synthetase short chain family member 2 (Acss2)

0.966705

(p = 0.717211)

0.884133

(p = 0.161879)

 

Fatty Acid Oxidation

  

Cpt1a

Acc: NM_031559.2

ID: 25757

Carnitine palmitoyltransferase 1a,

liver (CPT-1a)

0.929886

(p = 0.346192)

0.971389

(p = 0.737175)

Cpt1b

Acc: NM_013200.1

ID: 25756

Carnitine palmitoyltransferase 1b,

muscle (CPT-1B, M-CPT1)

0.705154↓

(p = 0.000182)

1.080327

(p = 0.411449)

Cpt1c

Acc: NM_001034925.2

ID: 308579

Carnitine palmitoyltransferase 1c (CPT 1C, CPT1-B, CPTI-B)

0.912484

(p = 0.292825)

1.076052

(p = 0.61451)

Cpt2

Acc: NM_012930.1

ID: 25413

Carnitine palmitoyltransferase 2

(CPTII)

1.058655

(p = 0.394189)

1.03461

(p = 0.630057)

Acox1

Acc: NM_017340.2

ID: 506811

Acyl-CoA oxidase, palmitoyl (RATACOA1)

1.291301↑

(p = 0.000954)

1.086216

(p = 0.293942)

Acadl

Acc: NM_012819.1

ID: 25287

Acyl-CoA dehydrogenase, long chain (ACOADA, LCAD)

1.024278

(p = 0.778232)

0.976708

(p = 0.800795)

Acadm

Acc: NM_016986.2

ID: 24158

Acyl-CoA dehydrogenase, C-4 to C-12 straight chain (MCAD)

1.017514

(p = 0.84005)

0.917314

(p = 0.340538)

Acads

Acc: NM_022512.1

ID: 64304

Acyl-Coa dehydrogenase, C-2 to C-3 short chain (Scad)

0.645793↓

(p = 0.000149)

1.280965

(p = 0.065028)

Acadsb

Acc: NM_013084.1

ID: 25618

Acyl-CoA dehydrogenase, short/branched chain

0.775064

(p = 0.065038)

1.804414↑

(p = 0.00009)

Acadvl

Acc: NM_012891.1

ID: 25363

Acyl-CoA dehydrogenase very long chain (VLCAD)

0.785093↓

(p = 0.006311)

1.285064↑

(p = 0.003725)

Eci1

Acc: NM_017306.4

ID: 29740

Enoyl-CoA delta isomerase 1(Deci)

0.978982

(p = 0.785245)

1.134394

(p = 0.11201)

Echs1

Acc: NM_078623.2

ID: 140547

Enoy-CoA hydratase, short chain 1,

mitochondrial

0.764837↓

(p = 0.007566)

1.220593

(p = 0.080591)

Ehhadh

Acc: NM_133606.1

ID: 171142

Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase

0.64736↓

(p = 0.000141)

1.219944

(p = 0.061876)

Eci2

Acc: NM_001006966.1

ID:291075

Enoyl-CoA delta isomerase 2 (Peci)

0.899414

(p = 0.120824)

0.74287↓

(p = 0.000344)

 

Fatty Acid Synthesis/ De Novo

  
 

Lipogenesis

  

Gckr

Acc: NM_013120.2

ID: 25658

Glucokinase (hexokinase 4) regulator (GLRE)

0.755501

(p = 0.055196)

1.126918

(p = 0.490323)

Gck

Acc: NM_012565.1

ID: 24385

Glukokinase (GLUKA, RNGK2)

4.265985↑

(p = 6.89E-18)

0.302628↓

(p = 4.47E-11)

Pklr

Acc: NM_012624.3

ID: 24651

Pyruvate kinase, liver and RBC (PK1, PKL, Pklg)

2.097495↑

(p = 0.000451)

0.498737↓

(p = 0.000675)

Acly

Acc: NM_016987.2

NM_001111095.1

ID: 24159

ATP citrate lyase (ACL, Clatp)

1.295435↑

(p = 0.000403)

0.895746

(p = 0.143597)

Fasn

Acc: NM_01332.1

ID: 50761

Fatty acid synthase

1.08142

(p = 0.423101)

0.904824

(p = 0.357733)

Me1

Acc: NM_012600.2

ID: 24552

Malic enzyme 1, NADP(+)-dependent, cytosolic (MOD1)

0.847973

(p = 0.065373)

0.990152

(p = 0.920281)

Me2

Acc: NM_001111095.1

ID: 307270

Malic enzyme 2, NAD(+)-dependent, mitochondrial

Scd1

Acc: NM_139192.2

ID: 246074

Stearyol-Coenzyme A desaturase 1

9.92997↑

(p = 0.00E + 00)

0.367553↓

(p = 3.10E-28)

Elovl1

Acc: NM_001044275.1

ID: 67953.2

ELOVL fatty acid elongase 1

0.696973↓

(p = 0.)

and

1.025883

(p = 0.77018)

1.502326↑

(p = 5.63E-09)

and

1.199776

(p = 0.056696)

Elovl2

Acc: NM_001109118.1

ID: 498728

ELOVL fatty acid elongase 2

0.712072

(p = 0.389679)

0.330644

(p = 0.176175)

Elovl4

Acc: NM_001191796.1

XM_001062735.2

ID: 315851

ELOVL fatty acid elongase 4

1.053677

(p = 0.719414)

0.950803

(p = 0.678269)

Elovl5

Acc: NM_134382.1

ID: 171400

ELOVL fatty acid elongase 5 (rELO1)

1.027579

(p = 0.719414)

2.101966↑

(p = 1.14E-17)

Elovl6

Acc: NM_134383.2

ID: 171402

ELOVL fatty acid elongase 6 (Lce2, rELO2)

0.511033↓

(p = 2.11E-11)

and

1.322709↑

(p = 0.037357)

1.436011↑

(p = 0.001273)

and

0.797587

(p = 0.0795)

Fads1

Acc: NM_053445.2

ID: 84575

Fatty acid desaturase 1

1.16415

(p = 0.102452)

0.828712↓

(p = 0.042428)

Fads2

Acc: NM_031344.2

ID: 83512

Fatty acid desaturase 2 (Fadsd6)

1.036468

(p = 0.84278)

0.890867

(p = 0.485008)

Mlcyd

Acc: NM_053477.1

ID: 85239

Malonyl-CoA decarboxylase

1.06015

(p = 0.581558)

0.800024↓

(p = 0.047506)

 

Triglyceride (TG) Synthesis/VLDL-TG Assembly

  

Agpat1

Acc: NM_212458.1

ID: 406165

1-Acylglycerol-3-phosphate O-acyltransferase 1

1.733174↑

(p = 0.000011)

0.551598↓

(p = 0.000015)

Agpat2

Acc: NM_001107821.1

ID: 311821

1-Acylglycerol-3-phosphate O-acyltransferase 2

0.890825

(p = 0.154834)

0.98959

(p = 0.895733)

Agpat3

Acc: NM_001106378.1

ID: 311821

1-Acylglycerol-3-phosphate O-acyltransferase 3

0.625706↓

(p = 0.004796)

1.138055

(p = 0.352178)

Agpat6

Acc: NM_001047849.1

ID: 305166

1-Acylglycerol-3-phosphate O-acyltransferase 6 (RGD1310520)

0.668305↓

(p = 0.754188)

1.483745↑

(p = 0.000001)

Agpat9

Acc: 001025670.1

ID: 305166

1-Acylglycerol-3-phosphate O-acyltransferase 9

0.702126↓

(p = 0.007365)

1.461539↑

(p = 0.002906)

Mogat1

Acc: NM_001108803.1

ID: 363261

Monoacylglycerol O-acyltransferase 1

0.911577

(p = 0.405954)

0.977825

(p = 0.860977)

Dgat1

Acc: NM_053437.1

ID: 84497

Diacylglycerol O-acyltransferase 1 (ARAT, Dgat)

0.766526↓

(p = 0.033377)

1.35964↑

(p = 0.012554)

Dgat2

Acc: NM_001012345.1

ID: 252900

Diacylglycerol O-acyltransferase 2 (ARAT)

1.000764

(p = 0.992838)

0.890682

(p = 0.159626)

Arf3

Acc: NM_080904.2

ID: 140940

ADP-ribosylation factor 3 (AC1-253)

1.253088↑

(p = 0.000991)

0.745999↓

(p = 0.000289)

 

Cholesterol Synthesis/Metabolism

  

Acat2

Acc: NM_001006995.1

ID: 308100

Acetyl-CoA acetyltransferase 2 (Acat3, Ab2-076)

1.149942

(p = 0.064026)

0.846982↓

(p = 0.020354)

Hmgcr Acc: NM_013134.2 ID: 25675

3-Hydroxy-3-methylglutaryl-CoA reductase (3H3M)

0.614003↓ (p = 0.000734)

1.212062 (p = 0.155741)

Insig 1

Acc: NM_022392.1

ID: 64194

Insulin induced gene 1

1.046145

(p = 0.573908)

0.618888↓

(p = 0.000006)

Insig 2

Acc: NM_178091.4

ID: 288985

Insulin induced gene 2

0.823541

(p = 0.133816)

1.467193↑

(p = 0.003866)

Ldlr

Acc: NM_175762.2

ID: 300438

Low density lipoprotein receptor (LDLRA)

0.761982

(p = 0.148211)

1.204468

(p = 0.362466)

Mvk

Acc: NM_031063.1

ID: 81727

Mevalonate kinase (Lrbp)

1.024571

(p = 0.839357)

1.168772

(p = 0.150024)

Npc1

Acc: NM_001002025.11

ID: 266732

Niemann-Pick disease, type C1 (Cdig2)

0.838672

(p = 0.861612)

1.21535

(p = 0.847542)

 

Proteins Involved in Lipid Clearance

  

Abca4

Acc: NM_00110772.1

ID: 310836

ATP-binding cassette, subfamily A (ABC1), member 4 (ABCR)

Abcb4

Acc: NM_012690.1

ID: 24891

ATP-binding cassette, subfamily B (MDR/TAP), member 4 (Mdr2, Pgy3)

1.290231

(p = 0.284859)

0.894225

(p = 0.438512)

Abcb11

Acc: NM_031760.1

ID: 83569

ATP-binding cassette, subfamily B (MDR/TAP), member 11 (Bsep, Spgp)

0.693218

(p = 0.05412)

1.397109

(p = 0.086006)

Abcc3

Acc: NM_080581.1

ID: 140668

ATP-binding cassette, subfamily C (CFTR/MRP), member 3 (Mlp2, Mrp3)

0.930144

(p = 0.499966)

0.930223

(p = 0.509623)

Abcc6

Acc: NM_031013.1

ID: 81642

ATP-binding cassette, subfamily C (CFTR/MRP), member 6 (Mrp6)

1.044104

(p = 0.931493)

0.953551

(p = 0.836794)

Abcd1

Acc: NM_001108821.1

ID: 363516

ATP-binding cassette, subfamily D (ALD), member 3 (RGD1562128)

0.981591

(p = 0.867544)

0.973671

(p = 0.807543)

Abcd3

Acc: NM_012804.1

ID: 25270

ATP-binging cassette, subfamily D (ALD), member 3 (PMP70, Pxmp1)

0.775986↓

(p = 0.000407)

1.067058

(p = 0.3708)

Abcg2

Acc: NM_181381.2

ID: 312382

ATP-binding cassette, subfamily G (WHITE), member 2 (BCRP1)

0.840673

(p = 0.694657)

1.966469

(p = 0.051575)

Abcg5

Acc: NM_053754.2

ID: 114628

ATP-binding cassette, subfamily G (WHITE), member 5

1.289574

(p = 0.31897)

0.839246

(p = 0.375668)

Apoa4

Acc: NM_012737.1

ID: 25080

Apolipoprotein A-IV (Apo-AIV, ApoA-IV, ApoAIV)

1.975251↑

(p = 0.005407)

0.701419

(p = 0.119689)

Apob

Acc: NM_019287.2

ID: 54225

Apolipoprotein B (Aa1064, AC1-060, Apo B-100, ApoB-100, ApoB-48)

0.90111

(p = 0.750761)

1.187596

(p = 0.618021)

Apoc2

Acc: NM_001085352.1

ID: 292697

Apolipoprotein C-II (RGD1560725)

2.057009↑

(p = 0.000592)

0.532413↓

(p = 0.000001)

Apoc3

Acc: NM_012501.1

ID: 24207

Apolipoprotein C-III (ApoC-III, apo-CIII)

0.684698↓

(p = 0.000263)

1.307856↑

(p = 0.008469)

Apoe

Acc: NM_138828.2

ID: 25728

Apolipoprotein E (APOEA)

1.485673↑

(p = 0.000003)

0.778654↓

(p = 0.004399)

Apof

Acc: NM_001024351.1

ID: 500761

Apolipoprotein F

Lpl

Acc: NM_012498.2

ID: 24539

Lipoprotein lipase

1.135422

(p = 0.100839)

0.812916↓

(p = 0.007915)

Vldlr

Acc: NM_013155.2

ID: 25696

Very low density lipoprotein receptor

0.6722↓

(p = 0.000001)

Or

0.486999↓

(p = 8.10E-08)

1.096751

(p = 0.283284)

Or

1.520316↑

(p = 0.002103)

Ppt1

Acc: NM_022502.2

ID: 29411

Palmitoyl-protein thioesterase 1 (Ppt)

0.9252

(p = 0.307699)

1.076592

(p = 0.320819)

(p = 0.192733)

 

Central Metabolic Regulators (Lipid Transcription Factors)

  

Foxa1

Acc: NM_012742.1

ID: 25098

Forkhead box A1

0.828962

(p = 0.418498)

1.067287

(p = 0.72547)

Hnf4a

Acc: NM_022180.1

ID: 25735

Hepatocyte nuclear factor 4, alpha (Hnf4alpha, Hnf4a)

1.208695

(p = 0.660749)

0.934321

(p = 0.806661)

Mlxipl

Acc: NM_133552.1

ID: 171078

MLX interacting protein-like (ChREBP, WS-bHLH, Wbscr14, bHLHd14)

1.019326

(p = 0.831873)

1.23554↑

(p = 0.015243)

Nr1h3

Acc: NM_031627.2

ID: 58852

Nuclear receptor subfamily 1, group H, member 3 (LXRalpha)

0.898224

(p = 0.132662)

1.22274↑

(p = 0.00316)

Ppara

Acc: NM_013196.1

ID: 25747

Peroxisome proliferator activated receptor alpha (PPAR)

1.042152

(p = 0.702728)

1.34318↑

(p = 0.01657)

Ppard

Acc: NM_013141.2

ID: 25682

Peroxisome proliferator activated receptor delta (Pparb)

1.049635

(p = 0.640966)

and

1.023475

(p = 0.858495)

1.001442

(p = 0.988966)

and

0.929482

(p = 0.61664)

Pparg

Acc: NM_013124.3

NM_001145366.1

NM_001145367.1

ID: 25664

Peroxisome proliferator activated receptor gamma

1.140175

(p = 0.07102)

0.96347

(p = 0.648174)

Ppargc1a

Acc: NM_031347.1

ID: 83516

Peroxisome proliferator activated receptor gamma, coactivator 1 alpha (Ppargc1)

2.166136↑

(p = 0.013221)

0.49897

(p = 0.089406)

Ppargc1b

Acc: NM_176075.2

ID: 291567

Peroxisome proliferator activated receptor, coactivator 1 beta (PGC1beta, Perc)

0.787663↓

(p = 0.007863)

1.092996

(p = 0.296335)

Srebf1

Acc: XM_213329.5

XM_001075680.2

ID: 78968

Sterol regulatory element binding transcription factor 1 (ADD-1, ADD1, SREBP-1, SREBP-1c, Srebp1)

0.810661↓

(p = 0.012341)

and

0.885992

(p = 0.449261)

1.17608

(p = 0.063087)

and

1.460992↑

(p = 0.011985)

Srebf2

Acc: NM_001033694.1

ID: 300095

Sterol regulatory element binding transcription factor 2 (SREBP-2, SREBP2-retired, Srebf2)

0.854579

(p = 0.062966)

0.964258

(p = 0.651328)

Xbp1

Acc: NM_001004210.1

ID: 289754

X-box binding protein 1 (HTF)

1.168979

(p = 0.087563)

1.080755

(p = 0.380509)

Discussion

The objective of this study was to examine the effects of dietary administration of NDGA on gene expression involved in lipid homeostasis in liver, skeletal muscle and adipose tissue in rats chronically fed a 60 % fructose diet. A secondary goal was to utilize the information about the expression patterns of genes to identify lipid genes and pathways and modulators of lipid metabolism that might be the targets of NDGA amelioration of hypertriglyceridemia and hepatic steatosis. We examined gene expression in liver, gastrocnemius muscle (a representative of skeletal muscle) and white adipose tissue when rats were fed a chow, or HFrD supplemented with ± NDGA. We selected liver, skeletal muscle and adipose tissue for the following reasons: 1) the liver is a major organ responsible for fatty acid catabolism, de novo lipid synthesis (lipogenesis), triglyceride synthesis and export in the form of VLDL-TG; 2) skeletal muscle is a major site of fatty acid oxidation; and 3) fat stored as triglyceride in adipose tissue and mobilized in the form of plasma free fatty acids (FFAs) is the major fuel reserve and fuel source. In addition, all three tissues are highly sensitive to insulin action. We identified a number of genes involved in fatty acid oxidation, lipogenesis, and lipid clearance, as well as transcription factors influencing lipid metabolism, whose expression was significantly altered in response to NDGA treatment in these three tissue types.

As reported previously, and confirmed here, after 16 weeks on a diet in which about 67 % of kcals are derived from fructose, the rats developed hyperinsulinemia (insulin resistance), hypertriglyceridemia and hepatic steatosis [47, 56, 68]. Additionally, our results demonstrated that the dietary administration of NDGA greatly attenuated the HFrD induced hepatic steatosis and plasma triglyceride levels. Given that hepatic steatosis and dyslipidemia result from an imbalance in lipid homeostasis in the liver when fatty acid uptake or de novo lipogenesis outweighs lipid oxidation or export. Accordingly, we first examined the effects of HFrD and HFrD + NDGA feeding on the expression of key genes involved in hepatic fatty acid uptake, fatty acid oxidation and thioesterification/activation of fatty acids catalyzed by acyl-CoA synthetase enzymes, which is required for fatty acid catabolism, de novo lipogenesis and remodeling of biological membranes. Whereas expression of fatty acid transporter Slc27a1 (FATP1) was not affected by high-fructose feeding, expression of Slc27a2 (FATP2) was significantly upregulated. Likewise, although HFrD + NDGA treatment had no effect on the mRNA levels of Slc27a1, co-treatment with NDGA prevented the HFrD-induced expression of Slc27a2. We further observed that NDGA upregulated the expression of several genes for enzymes involved in fatty acid oxidation, including Cpt1b, Cpt2, Acox1, Acadvl, Eci and Ehbadh. In addition, our data provide evidence that NDGA differentially impacted the PPARα target genes for the enzymes involved in fatty acid thiolation/ activation (synthesis of acyl-CoAs); it increased the expression of acyl-CoA synthetase long-chain family member 1 (Acsl1) and acyl-CoA synthetase medium-chain family member 3 (Acsm3), but attenuated the levels of acyl-CoA synthetase long-chain family member 4 (Acsl4) and acyl-CoA synthetase short-chain family member 2 (Acss2). These acetyl-CoA synthetases vary in their substrate specificity and partitioning of fatty acids towards diverse cellular metabolic pathways. Acsl1shows preference for long chain saturated and monounsaturated fatty acids C16 to C18, whereas Acsl4 shows specificity for polyunsaturated fatty acids C20:4 and C20:5 [65]. Acsm3 acts on medium chain fatty acids C4 to C11 and catalytic function of Acss2 is to catalyze the activation of acetate (short chain) for use in lipid synthesis. Since C4-C18 fatty acids are mainly oxidized via mitochondrial β-oxidation, it is likely that NDGA induces the expression of Acsl1 and Acsm3 in an effort to promote increased channeling of the hepatic medium and long chain fatty acids for their catabolism via mitochondrial β-oxidation. Besides, we observed that NDGA treatment increased the gene expression of PPARα transcription factor, a member of the nuclear hormone receptor superfamily [60]. It is considered a master regulator of oxidative catabolism of fatty acids for energy production, is expressed at high levels in metabolically active tissues such as heart, liver, skeletal muscle and kidney, and controls the transcription of many genes involved in mitochondrial and peroxisomal β-oxidation and microsomal ω-oxidation of fatty acids, with liver being its major site of action [60, 64]. Some of the genes involved in fatty acid uptake and activation, such as SLC27A2, Acsl1, Acsl4, Acm3 and Acss2, are also the targets of PPARα [64].

In this study, NDGA also markedly increased the expression of both PPARα and PPARβ/δ in skeletal muscle, which was accompanied by increased expression of several genes for enzymes involved in fatty acid uptake, activation and oxidation, including Cpt1c, Acox1, Acadsb, Eci, Ehhadh, FATP2 (Slc27a2) and Acss2. Few genes were downregulated in response to NDGA treatment, including Cpt1a, Cpt1b, Eci2, Acsl2 and FATP1 (Slc27a1). It is unclear why NDGA treatment decreased the expression of three fatty acid catabolizing genes, Cpt1a, Cpt1b and Eci2. Also, it is surprising that NDGA treatment caused simultaneous mRNA induction of both PPARα and PPARβ/δ, given that in skeletal muscle, these PPARs show redundancy in their functions as regulators of fatty acid homeostasis [66]. Moreover, unlike in the liver and heart, PPARβ/δ is several-fold more abundant in skeletal muscle than PPARα [62, 63, 66, 67, 69] and that the β/δ-sub-type can compensate for deficiency of PPARα in this tissue [66]. In addition, the metabolic significance of NDGA induction of skeletal muscle PPARα is not apparent given that PPARα gain-of-function and loss-of-function studies in mice have shown that the activity of the skeletal muscle PPARα pathway is directly linked to the development of insulin resistance, glucose intolerance, and diabetes [70]. More specifically, it has been said that overexpression of PPARα in skeletal muscle increases the expression of genes for fatty acid uptake and oxidation, protects mice against diet-induced obesity, but decreases the expression of the glucose transporter Glut4, resulting in animals becoming insulin resistant and glucose intolerant [70]. In contrast, diet-induced insulin resistance was prevented in PPARα-/- mice despite the development of obesity. Our previous studies, however, have shown that treatment of high-fat diet fed mice [59] and high-fructose diet fed rats [68] with NDGA improves whole body insulin resistance and glucose intolerance. Obviously, more experimental evidence will be needed to sort out the role of PPARα in skeletal muscle. Similar to liver and skeletal muscle, NDGA treatment also increased the expression of PPARα in white adipose tissue (WAT); however, it did not significantly impact the expression of genes for enzymes/proteins involved in fatty acid uptake and oxidation. The lack of effect of NDGA on fatty acid oxidative genes in adipose tissue is likely due to the fact that the fatty acid storage function of adipose tissue-specific PPARγ2 predominates over that of the oxidative function of PPARα [71, 72].

A reduction in hepatic lipogenesis appears to be an alternative mechanism for the lipid-lowering effect of NDGA. While high-fructose feeding increased the expression of sterol regulatory element-binding protein-1c (SREBP-1c) [73, 74] and carbohydrate responsive element-binding protein (ChREBP or Mlxipl) [74, 75], the two transcription factors that primarily regulate hepatic de novo lipogenesis (DNL), NDGA treatment prevented the upregulation of these transcription factors. The nutrition-sensitive SREBP-1c regulates the expression of hepatic lipogenic enzymes (FAS, ACL, ME, S14, SCD1, GPAT1, FADS1, FADS2, ELOVL5, ELOVL6, MTTP, G6PD) and glycolytic enzymes (GCK, PKLR) [73,74] in response to insulin [75, 76], whereas ChREBP regulates some of these genes (L-PK, SREBP-1c, ACL, FAS, ACC, S14, DGAT2, ME, ELOVL2, GLUT4, GCKR) [77, 78] in response to high glucose [76, 79]. NDGA treatment markedly reduced the expression of a large number of SREBP-1c and/or ChREBP target genes including Acly, Fasn, Scd1, Elovl2, Elovl5, Fads1, Fads2, DGAT2 and Pklr as compared to rats fed a high-fructose diet alone. Surprisingly, NDGA treatment also increased the gene expression of a few genes, such as Elovl4, Elovl6, and Mogat1. The reason for their upregulation is not clear, but may be related to the fact that these genes, along with several other lipogenic genes, are also regulated by PPARα [64], whose expression, as noted above, is upregulated in response to NDGA treatment. NDGA also increased (Lpl, Vldr) and decreased (Apoa4, Apof) the expression of genes involved in lipid clearance. Again, Lpl and Vldr are known targets of PPARα [64]. Interestingly, expression of hepatic glycolytic genes, Gck and Gckr, was decreased by NDGA treatment; glucokinase (GCK) in liver and pancreatic β-cells is subject to inhibition by glucose regulatory protein (GCKR) [80, 81]. The inhibitory effect of GCKR depends on the presence of fructose-6-phosphate (F6P) and is antagonized by fructose-1-phosphate (F1P) [80, 81]. The NDGA inhibition of Gck is likely to contribute to NDGA-mediated attenuation of lipogenesis, since GCK is the rate-limiting enzyme of glycolysis in the liver, and stimulates glycolysis and lipogenesis by enhancing glucose flux, including production of acetyl-CoA for lipid synthesis [82]. The simultaneous inhibition of expression of both Gck and Gckr in response to NDGA could be explained on the basis of NDGA-mediated inhibition of SREBP-1c and ChREBP; Gck is a known target of SREBP-1c [73, 74], whereas Gckr is regulated by ChREBP [77]. In addition, NDGA-inhibition of Gck may further limit lipogenesis, given that GCK also stimulates glycolysis and lipogenesis at the transcription level via ChREBP [79].

In addition, we found that NDGA increased the gene expression of malonyl decarboxylase (Mlycd) enzyme, which catalyzes the degradation of malonyl-CoA to acetyl-CoA [83]. Therefore, it is likely that the availability of malonyl-CoA as a substrate for lipogenesis is substantially lower in the livers of NDGA treated animals, and, thus, limits the extent of lipogenesis. Apart from its role as the immediate precursor for de novo synthesis of fatty acids, malonyl-CoA plays an important role in regulating hepatic fatty acid oxidation as a potent inhibitor of carnitine palmitoyitransferase [84, 85]. Therefore, NDGA-dependent increases in Mlycd expression and subsequently decreases in malonyl-CoA levels may stimulate mitochondrial transport of fatty acids for their mitochondrial β-oxidation. Interestingly, Mlycd is a potent target of PPARα [64, 86, 87].

Similar to the liver, NDGA treatment differentially impacted the genes for enzymes/proteins involved in de novo lipogenesis, elongation and desaturation of fatty acids, triglyceride synthesis and lipid clearance in skeletal muscle and adipose tissue. These changes, as discussed above for the liver, are likely to result from interplay between PPARα, PPARβ/δ, PPARγ, SREBP-1c, and ChREBP in a skeletal muscle and adipose tissue specific manner. Surprisingly, no NDGA-induced changes in Mlycd expression were noted in either skeletal muscle or adipose tissue. Other studies have previously reported significant changes in Mlycd levels in both tissues under variable physiological conditions [88, 89]. Since Mlcyd is also regulated by AMPK by a phosphorylation/dephosphorylation mechanism, it is possible that NDGA may stimulate enzymatic activity by promoting its AMPK-mediated phosphorylation [89]. This is a likely possibility given that NDGA treatment causes a robust stimulation of AMPK activity via its increased phosphorylation.

Conclusions

In conclusion, our study shows that chronic dietary treatment with NDGA can attenuate high-fructose diet-induced hypertriglyceridemia and hepatic steatosis (TG accumulation). DNA microarray analysis showed that dietary NDGA profoundly affects the gene expression profiles in liver and skeletal muscle. However, adipose tissue was less dramatically impacted by NDGA treatment. Analysis indicated that NDGA differentially increased the expression of enzymes involved in hepatic fatty acid oxidation and of proteins that facilitate fatty acid transport. The changes were generally greater in liver and skeletal muscle than in adipose tissue. The high-fructose diet containing NDGA also altered the expression of genes related to proteins/enzymes of de novo fatty acid and triglyceride synthesis and lipid clearance. On the basis of the experimental data obtained, the beneficial actions of NDGA on hypertriglyceridemia and steatosis are exerted by a dual mechanism: inhibition of lipogenesis and enhanced functional expression of the key genes for enzymes/proteins involved in fatty acid β-oxidation pathway in liver and skeletal muscle. In adipose tissue, although NDGA inhibits the expression of major enzymes involved in lipogenesis, it also promotes lipid storage by upregulating the expression of TG synthesizing enzymes and attenuating the mRNA levels of proteins that catalyze TG hydrolysis.

Methods

Materials

Oil Red O was obtained from Sigma-Aldrich (St. Louis, MO). Glucose, TG, FFA, and cholesterol measurement kits were obtained from Stanbio Laboratory (Boerne, TX). The rat insulin RIA Kit was obtained from EMD Millipore (Billerica, CA). 60 % Fructose diet (high fructose diet [HFrD] #TD.89247; formula g/Kg: Casein 207; DL-Methionine 3.0; Fructose 600.0; Lard 50.0; Cellulose79.81; Mineral Mix, Rogers-Harper [170760] 50.0; Zinc Carbonate 0.04; Vitamin Mix, Teklad [40060] 10.0 and Green Color 0.15; percent by weight [% kcal from]: Protein 18.3 [20.2]; Carbohydrate 60.4 [66.8]; and Fat 5.2 [13.0]) from Envigo Teklad Diets, Madison, WI. 60 % Fructose diet supplemented with NDGA (2.5 NDGA/kg HFrD) was also custom made by Envigo Teklad Diets. All other reagents used were of analytical grade.

Animals and treatments

All animal experiments were performed according to the procedures approved by the VA Palo Alto Health Care System Animal Care and Use Committee (IACUC). Male Sprague-Dawley (SD) rats, obtained from Harlan Sprague-Dawley (Indianapolis, IN), were used in these studies. For dietary treatment of rats with NDGA, groups of SD rats were fed a standard chow diet for 1 week to acclimatize them to a new environment. Subsequently, one group of rats switched to HFrD supplemented with 2.5 g NDGA/g HFrD and was maintained on this diet for 16 weeks. The second group of SD rats was maintained on HFrD alone for 16 weeks, while a third group of rats continued to be fed a chow diet for 16 weeks. Before, during, and at the end of the feeding period, blood samples were taken from the tails of rats for analyses of serum metabolites after 4 h of fast. At the end of the 16-wk treatment period, the rats were fasted, blood was collected, and rats were subsequently euthanized. Blood samples were centrifuged at 4,000 x g for 15 min at 4 °C and the recovered serum samples were stored at –80 °C until analyzed for various metabolites. Liver, skeletal muscle (mixed gastrocnemius; ~3 % type I fiber, ~6 % type IIA fiber, ~34 % type IID/X fiber and ~57 % type IIB fiber) [90] and white adipose tissue (WAT, epididymal) were excised immediately, weighed, frozen in liquid nitrogen, and stored at –80oC until utilized for gene array analysis, the quantification of liver TG content or Oil Red O staining of frozen sections for steatosis evaluation.

Measurement of serum triglyceride, cholesterol, glucose, free-fatty acids and insulin levels

Serum glucose, triglyceride, free-fatty acids and total cholesterol levels were determined with commercial assay kits (Stanbio Laboratory, Boerne, TX). Serum insulin levels were quantified using a rat specific insulin RIA Kit (EMD Millipore, Billerica, CA).

Quantification of hepatic triglyceride content

Suitable aliquots of liver tissue homogenates were extracted with chloroform-methanol according to the procedure of Folch et al [91], and extracted lipid samples were analyzed for their TG content with an enzymatic assay kit as noted above.

Whole genome microarray

RNA samples for the whole genome microarray (Rat OneArray® v1) were isolated from the liver, white adipose tissue (epididymal) and skeletal muscle (gastrocnemius) using Qiagen RNeasy Plus Mini Kit (Valencia, CA). The RNA analysis, including integrity and quantitation of RNA, was carried out using an Agilent RNA 6000 Nano Kit and an Agilent Bioanalyzer System (Agilent Technologies, Santa Clara, CA). Total RNA was pooled in an equal amount from individual rats of each group and treated with DNase I to remove residual genomic DNA. cDNA synthesis, Cy5-labelling and hybridization to the GeneChip GPL 13694 (rat OneArray® v1) were performed by PhalanxBio, Inc. (San Diego, CA). This assay is designed to generate amplified and Cy5 sense-strand DNA targets from the entire expressed genome without bias. Three repeats from each group were performed. The microarray data files have been submitted to the Gene Expression Omnibus; the accession number is GSE81346 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81346).

Differential and cluster gene expression analysis

The raw data from microarrays were analyzed using Partek Genomics Suite software, version 6.3 copyright 2008 (Partek Inc., St. Louis, MO). Briefly, GenePix Results (GPR) files containing the hybridization intensity were imported, followed by quintile normalization and log2 transformation to represent gene expression levels. Liver samples were grouped into: 1) standard chow diet fed (control); 2) high-fructose diet (HFrD)-fed; and 3) HFrD-NDGA fed animals. Three-way ANOVA was performed including diet (chow and HFrD) and NDGA interaction to generate the lists of differentially expressed genes comparing chow, HFrD and HFrD-NDGA. There were three microarrays for each group. For the comparison between chow-fed and HFrD-fed rats, probe sets with a fold change of 2.0 and adjusted P value <0.05 were considered differentially expressed. For the comparison between the HFrD and HFrD-NDGA groups, the analyses were also set with a fold change of 2.0 and adjusted P value of <0.05. The Benjamini-Hochberg false discovery rate (FDR) method was used to select the regulated genes with the lowest FDR. Partek Genomics Suite was used as the first step for quality control of the data on all the samples with two methods: Pearson correlation and Principal Component Analysis (PCA). PCA was performed as a global view of sample clustering, which is related to the total variance in gene expression for all genes. Normalized expression values for all genes were analyzed.

Pathway analysis

For each comparison, a list of differentially expressed genes was generated. The gene list, along with associated expression or fold-change values, were further analyzed using Ingenuity Pathway Analysis (Ingenuity Systems, Inc., Redwood City, CA) to identify differentially expressed pathways induced by HFrD feeding or NDGA in HFrD rats. The list of significantly regulated genes, selected by the microarray analysis described above, was loaded in IPA with the following criteria: direct and indirect relationships filtered by species (rat) and by tissue (liver, gastrocnemius or adipose tissue). Then IPA computed the data to generate significant networks of genes that are associated with particular biological functions, diseases and metabolic/signaling pathways.

Oil Red O staining of liver sections for detection of neutral lipids

Liver samples were collected from rats, embedded in Tissue Freezing Medium (Leica Microsystems Inc., Buffalo Grove, IL), and stored at -80 °C until used for sectioning to 8-μM slices. Liver sections were stained with Oil Red O for the visualization of neutral lipids stored in the lipid droplets by using a slight modification of the standard procedure as described earlier from this laboratory (59).

Statistical analysis

All of the data are expressed as the means ± S.E. One way and two-way ANOVA were used to study differences among groups. This was followed by a post hoc comparison using Bonferroni’s multiple-comparison test when necessary. Differences at P < 0.05 were considered statistically significant. Prism 5 software (GraphPad, La Jolla, CA) was used for all of the statistical calculations.

Abbreviations

FC: 

Free cholesterol

FFAs: 

Free fatty acids

HFrD: 

High-fructose rich diet

MetS: 

Metabolic syndrome

NDGA: 

Nordihydroguaiaretic acid

NAFLD: 

Non-alcoholic fatty liver disease

NASH: 

Nonalcoholic steatohepatitis

TC: 

Total cholesterol

TG: 

Triglyceride

Declarations

Acknowledgements

This work was supported by National Institutes of Health, NHLBI Grant 1R01HL92473, and the Office of Research and Development, Medical Service, Department of Veterans Affairs.

Availability of data and material

The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

Authors’ contributions

Conceived and designed the experiments: HZ, WJS, FBK, SA. Performed the experiments: HZ, YL, YFC, JT. Analyzed the data: HZ, AB, SB, WJS. Prepared illustrations: AB, WJS. Wrote the Manuscript: WJS, FBK, SA. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Geriatric Research, Education and Clinical Center, VA Palo Alto Health Care System
(2)
Division of Endocrinology, Stanford University
(3)
Present Address: Department of Pathology, Keck School of Medicine, University of Southern California
(4)
Present Address: Department of Pediatrics, Saint Louis University School of Medicine

References

  1. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old question and new insights. Science. 2011;332(6037):1519–23.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Vernon G, Baranova A, Younossi ZM. Systematic Review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–85.View ArticlePubMedGoogle Scholar
  3. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of nonalcoholic fatty liver disease (NAFLD) and diagnostic accuracy of noninvasive tests for liver disease severity. Ann Med. 2011;43:617–49.View ArticlePubMedGoogle Scholar
  4. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686–90.View ArticlePubMedGoogle Scholar
  5. Kawano Y, Cohen DE. Mechanism of hepatic triglyceride accumulation in nonalcoholic liver disease. J Gastroenterol. 2013;48(4):434–41.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Smith BW, Adams LA. Nonalcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48(3):97–113.View ArticlePubMedGoogle Scholar
  7. Wang DQ-H, Portincasa P, Neuschwander-Tetri BA. Steatosis in the liver. Comp Physiol. 2013;3:1493–532.View ArticleGoogle Scholar
  8. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99–S112.View ArticlePubMedGoogle Scholar
  9. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu Rev Pathol Mech Dis. 2010;5:145–71.View ArticleGoogle Scholar
  10. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10(11):656–65.View ArticlePubMedGoogle Scholar
  11. Alameda-Valdes P, Cuevas-Ramos D, Aquilar-Salinas CA. Metabolic syndrome and nonalcoholic fatty liver disease. Ann Hepatol. 2009;8 Suppl 1:18–24.Google Scholar
  12. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–44.View ArticlePubMedGoogle Scholar
  13. Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4):637–53.View ArticlePubMedGoogle Scholar
  14. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143(10):722–8.View ArticlePubMedGoogle Scholar
  15. Marchesini G, Bugianesi B, Forlani G, Cerrelli F, Lenzi M, Maini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver steatohepatitis, and metabolic syndrome. Hepatology. 2003;37(4):917–23.View ArticlePubMedGoogle Scholar
  16. Rector RS, Thyfault JP, Wei Y, Ibdak JA. Nonalcoholic fatty liver disease and metabolic syndrome. World J Gastroenterol. 2008;14(2):185–92.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 2011;7(8):456–65.View ArticlePubMedGoogle Scholar
  18. Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34(1):84–129.View ArticlePubMedGoogle Scholar
  19. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato SM, Fruchart J-C, James PT, Loria CM, Smith Jr SC. Harmonizing the metabolic syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.View ArticlePubMedGoogle Scholar
  20. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28:629–36.View ArticlePubMedGoogle Scholar
  21. O’Neill S, O’Driscoll L. Metabolic syndrome. a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015;16:1–12.View ArticlePubMedGoogle Scholar
  22. Bhatia LS, Curzen NP, Byrne CD. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol. 2012;27(4):420–8.View ArticlePubMedGoogle Scholar
  23. Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol. 2014;20(37):13306–24.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50.View ArticlePubMedGoogle Scholar
  25. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the study of liver diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–609.View ArticlePubMedGoogle Scholar
  26. Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol. 2013;10(11):676–85.View ArticlePubMedGoogle Scholar
  27. Sourianarayanane AC, Pagadala MR, Kirwan JP. Management of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2013;59(1):69–87.PubMedGoogle Scholar
  28. Lim JS, Mietus-Snyder M, Valente A, Schwarz J-M, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gasteroenterol Hepatol. 2010;7:251–64.View ArticleGoogle Scholar
  29. Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol. 2013;9:13–27.View ArticlePubMedGoogle Scholar
  30. Neuschwander-Tetri BA. Carbohydrate intake and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2013;16:446–52.View ArticlePubMedGoogle Scholar
  31. Rector RS, Thyfault JP. Does physical inactivity cause nonalcoholic fatty liver disease? J Appl Physiol. 2011;111:1828–35.View ArticlePubMedGoogle Scholar
  32. Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology. 2013;57:2525–31.View ArticlePubMedGoogle Scholar
  33. Yasutake K, Kohjima M, Kotoh K, Nakashima M, Nakamuta M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:1756–67.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Bray GA, Popkin BM. Calorie-sweetened beverages and fructose: what we have learned 10 years later. Pediatr Obes. 2013;8:242–8.View ArticlePubMedGoogle Scholar
  35. Lustig RH. Fructose: It’s “alcohol without the buzz”. Adv Nutr. 2013;4:226–35.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Marriott BP, Cole N, Lee E. National estimates of dietary fructose increased from 1977 to 2004 in the United States. J Nutr. 2009;139:1228S–35S.View ArticlePubMedGoogle Scholar
  37. Park YK, Yetley EA. Intakes and food sources of fructose in the United States. Am J Clin Nutr. 1993;58:737S–47S.PubMedGoogle Scholar
  38. Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem. 2012;23:203–8.View ArticlePubMedGoogle Scholar
  39. Aeberli I, Hochuli M, Gerber PA, Sze L, Murer SB, Tappy L, Spinas GA, Bernes K. Moderate amounts of fructose consumption impairs insulin sensitivity in healthy young men. Diabetes Care. 2013;36:150–6.View ArticlePubMedGoogle Scholar
  40. Lê KA, Ith M, Kreis R, Faeh D, Bortolotti M, Tran C, Boesch C, Tappy L. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr. 2009;89:1760–5.View ArticlePubMedGoogle Scholar
  41. Moore JB, Gunn PJ, Fielding BA. The role of dietary sugars and de novo lipogenesis in nonalcoholic fatty liver disease. Nutrition. 2014;6:5679–703.Google Scholar
  42. Parks EJ, Skokan LM, Timlin MT, Dingfelder CS. Dietary sugars stimulates fatty acid synthesis in adults. J Nutr. 2008;138:1039–46.PubMedPubMed CentralGoogle Scholar
  43. Stanhope KL, Schwarz JM, Keim NL, Sc G, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhnag W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano T, Beysen C, Hellerstein MK, Berglund L, Havel PJ. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009;119:1322–34.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Welsh JA, Sharma A, Abramson JL, Vaccarino V, Gillespie C, Vos MB. Caloric sweetner consumption and dyslipidemia among US adults. JAMA. 2010;303:1490–7.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Bocarsly ME, Powell ES, Avena NM, Hoebel BG. High-fructose corn syrup causes characteristics of obesity in rats: increased body weight, body fat and triglyceride levels. Pharmacol Biochem Behav. 2010;97:101–6.View ArticlePubMedPubMed CentralGoogle Scholar
  46. DeBosch B, Chen Z, Saben JL, Finck BN, Moley KH. Glucose transporter 8 (Glut 8) mediates fructose–induced de novo lipogenesis and macrosteatosis. J Biol Chem. 2014;289:10989–98.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Gowri MS, Azhar RK, Kraemer FB, Reaven GM, Azhar S. Masoprocol decreases rat lipolytic activity by decreasing the phosphorylation of HSL. Am J Physiol Endocrinol Metab. 2000;279:E593–600.PubMedGoogle Scholar
  48. Ishimoto T, Lanaspa MA, Le M-PT, Garcia GE, Diggle CP, MacLean PS, Jackman MR, Asipu A, Roncal-Jimenez CA, Kosugi T, Rivard CJ, Maruyama S, Rodriguez-Iturbe B, Sánchez-Lozada LG, Bonthron DT, Sautin YY, Johnson RJ. Opposing effects of fructokinase C and A isoforms of fructose-induced metabolic syndrome in mice. Proc Natl Acad Sci U S A. 2012;109:4320–5.View ArticlePubMedPubMed CentralGoogle Scholar
  49. Mori T, Kondo H, Hase T, Murase T. Dietary phopsholipids ameliorate fructose-induced hepatic lipid and metabolic abnormalities in rats. J Nutr. 2011;141:2003–9.View ArticlePubMedGoogle Scholar
  50. Moon Y-A, Liang G, Xie X, Frank-Kamenetsky M, Fitzgerald K, Koteliansky V, Brown MS, Goldstein JL, Horton JD. The Scap/SREBP-pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab. 2012;15:240–6.View ArticlePubMedPubMed CentralGoogle Scholar
  51. Samuel VT. Fructose induced lipogenesis: from sugar to fat to insulin resistance. Trends Endocrinol Metab. 2011;22:60–5.View ArticlePubMedGoogle Scholar
  52. Thorburn AW, Storlien LH, Jenkins AB, Khouri S, Kraegen EW. Fructose-induced in vivo insulin resistance and elevated triglyceride levels in rats. Am J Clin Nutr. 1989;49:1155–63.PubMedGoogle Scholar
  53. Vos MB. Nutrition, nonalcoholic fatty liver disease and the microbiome: recent progress in the field. Curr Opin Lipidol. 2014;25:61–6.View ArticlePubMedPubMed CentralGoogle Scholar
  54. Arteaga S, Andrade-Cetto A, Cárdenas R. Larrea tridentate (Creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. J Ethinopharmacol. 2005;98:231–9.View ArticleGoogle Scholar
  55. Gowri MS, Reaven GM, Azhar S. Masoprocol lowers blood pressure in rats with fructose-induced hypertension. Am J Hypertens. 1999;12(7):744-6.Google Scholar
  56. Kelley GL, Allen G, Azhar S. High dietary fructose induces a hepatic stress response resulting in cholesterol and lipid dysregulation. Endocrinology. 2004;145:548–55.View ArticlePubMedGoogle Scholar
  57. Lee MS, Kim D, Jo K, Hwang JK. Nordihydroguaiaretic acid protects against high-fat diet-induced fatty liver by activating AMP-activated protein kinase in obese mice. Biochem Biophys Res Commun. 2010;401:92–7.View ArticlePubMedGoogle Scholar
  58. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Brignetti D, Luo J, Khandwala A, Reaven GM. Effect of masoprocol on carbohydrate and lipid metabolism in a rat model of type II diabetes. Diabetologia. 1999;42:102–6.View ArticlePubMedGoogle Scholar
  59. Zhang H, Shen W-J, Cortez Y, Kraemer FB, Azhar S. Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARα-dependent and –independent pathways. Am J Physiol Gastrointest Liv Physiol. 2013;304:G72–86.View ArticleGoogle Scholar
  60. Paper SR, Viswakarma N, Yu S, Reddy JK. PPARα: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal. 2010;8:e002.Google Scholar
  61. Lefebvre P, Chinetti G, Fruchart J-C, Staels B. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116:571–80.View ArticlePubMedPubMed CentralGoogle Scholar
  62. Abbott BD. Review of the expression of peroxisome proliferator-activated receptors alpha (PPARα, beta (PPARβ), and gamma (PPARγ) in rodent and human development. Reprod Toxicol. 2009;75:72–7.Google Scholar
  63. Wang Y-X. PPARs; diverse regulators in energy metabolism and metabolic diseases. Cell Res. 2010;20:124–37.View ArticlePubMedPubMed CentralGoogle Scholar
  64. Rakhshandehroo M, Knoch B, Müller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res 2010. 2010;612089.Google Scholar
  65. Lopes_Marques M, Cunha I, Reis-Henriques MA, Santos MM, Castro LF. Diversity and history of the long-chain acyl-CoA synthetase (Acsl) gene family in vertebrates. BMC Evol Biol. 2013;13:271.View ArticlePubMedPubMed CentralGoogle Scholar
  66. Muoio DM, MacLean PS, Lang DB, Shi L, Houmard JA, Way JM, Winegar DA, Corton JC, Dohm GL, Kraus WE. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) α knock-out mice: Evidence for compensatory regulation by PPARδ. J Biol Chem. 2002;277:26089–97.View ArticlePubMedGoogle Scholar
  67. Ehrenborg E, Krook A. Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor δ. Pharmacol Rev. 2009;61:373–93.View ArticlePubMedGoogle Scholar
  68. Zhang H, Li Y, Hu J, Shen W-J, Singh M, Hou X, Bittner A, Bittner S, Cortez Y, Tabassum J, Kraemer FB, Azhar S. Effect of Creosote bush-derived NDGA on expression of genes involved in lipid metabolism in liver of high-fructose fed rats: Relevance to NDGA amelioration of hypertriglyceridemia and hepatic steatosis. PLoS ONE. 2015;10(9):e0138203.View ArticlePubMedPubMed CentralGoogle Scholar
  69. Nakamura MT, Yudell BE, Loor JJ. Regulation of energy metabolism by long-chain fatty acids. Prog Lipid Res. 2014;53:124–44.View ArticlePubMedGoogle Scholar
  70. Finck BN, Bernal-Mizrachi C, Han DH, Coleman T, Sambandham N, LaRiviere LL, Holloszy JO, Semenkovich CF, Kelly DP. A potential link between muscle peroxisome proliferator-activated receptor-a signaling and obesity-related diabetes. Cell Metab. 2005;1:133–44.View ArticlePubMedGoogle Scholar
  71. Sample RK, Chatterjee VKK, O’Rahilly S. PPARγ and human metabolic disease. J Clin Invest. 2006;116:581–9.View ArticleGoogle Scholar
  72. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARγ. Annu Rev Biochem. 2008;77:289–312.View ArticlePubMedGoogle Scholar
  73. Amemiya-Kudo M, Shimano H, Hasty AH, Yahagi N, Yoshikawa T, Matsuzaka T, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Sato R, Kimura S, Ishibashi S, Yamada N. Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes. J Lipid Res. 2002;43:1220–35.PubMedGoogle Scholar
  74. Knebel B, Haas J, Harwig S, Jacob S, Köllmer C, Nitzgen U, Muller-Wieland D, Kotzka J. Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. PLoS ONE. 2012;7:e31812.View ArticlePubMedPubMed CentralGoogle Scholar
  75. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125–31.View ArticlePubMedPubMed CentralGoogle Scholar
  76. Xu X, So JS, Park JG, Lee AH. Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin Liver Dis. 2013;33:301–11.View ArticlePubMedPubMed CentralGoogle Scholar
  77. Ma L, Robinson LN, Towle HC. ChREBP•Mlx is the principal mediator of glucose-induced geen expression in the liver. J Biol Chem. 2006;281:28721–30.View ArticlePubMedGoogle Scholar
  78. Jeong Y-S, Kim D, Lee YS, Han J-Y, Im S-S, Chong HK, Cho Y-H, Kim WK, Osborne TF, Horton JD, Jun H-S, Ahn Y-H, Cha J-Y. Integrated expression profiling and genome-wide analysis of ChREBP targets reveals the dual role for ChREBP in glucose-regulated gene expression. PLoS ONE. 2011;6:e22544.View ArticlePubMedPubMed CentralGoogle Scholar
  79. Uyeda K, Repa JJ. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling glucose utilization and lipid synthesis. Cell Metab. 2006;4:107–10.View ArticlePubMedGoogle Scholar
  80. Anderka O, Boyken J, Aschenbach U, Batzer A, Boscheinen O, Schmoll D. Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: impact of physiological and pharmacological effectors. J Biol Chem. 2008;283:31333–40.View ArticlePubMedGoogle Scholar
  81. Zelent B, Raimondo A, Barrett A, Buettger CW, Chen P, Gloyn AL, Matschinsky FM. Analysis of the co-opertaive interaction between the allosterically regulated proteins GK and GKRP using tryptophan fluorescence. Biochem J. 2014;459:551–64.View ArticlePubMedPubMed CentralGoogle Scholar
  82. Foufelle E, Ferré P. New perpectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J. 2002;366:377–91.View ArticlePubMedPubMed CentralGoogle Scholar
  83. An J, Muoio DM, Shiota M, Fujimoto Y, Cline GW, Shulman GI, Koves TR, Stevens R, Millington D, Newgard CB. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med. 2004;10:268–74.View ArticlePubMedGoogle Scholar
  84. McGarry JD, Brown NF. The mitochondrial carnitine palmitoltransferase system. From concept to molecular analysis. Eur J Biochem. 1997;15:1–14.View ArticleGoogle Scholar
  85. Kerner J, Hoppel C. Fatty acid import into mitochondria. Biochim Biophys Acta. 2000;1486:1–17.View ArticlePubMedGoogle Scholar
  86. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JRB, Belke DD, Severson DL, Kelly DP, Lopaschuk GD. A role for peroxisome proliferator-activated receptor α (PPARα) in the control of cardiac malonyl-Coa Levels: Reduced fatty acid oxidation rtaes and increased oxidation rates in the hearts of mice lacking PPARα are associated with higher concentrtaions of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem. 2002;277:4098–103.View ArticlePubMedGoogle Scholar
  87. Lee GY, Kim NH, Zhao ZS, Cha BS, Kim YS. Peroxisomal-prolifertaor receptor α activated transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level. Biochem J. 2004;378:983–90.View ArticlePubMedPubMed CentralGoogle Scholar
  88. Saha AK, Schwarsin AJ, Rodunit R, Massé F, Kaushik V, Tornheim K, Prentki M, Ruderman NB. Activation of malonyl-COA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside. J Biol Chem. 2000;275:24279–83.View ArticlePubMedGoogle Scholar
  89. Park H, Kaushik VK, Constant S, Prentki M, Przybytkowski E, Ruderman NB, Saha AK. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycewrol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in response to exercise. J Biol Chem. 2002;277:32571–7.View ArticlePubMedGoogle Scholar
  90. Delp MD, Duan C. Composition and size of type I, IIA, IID/X, and IIB fibers and citrate synthase activity of rat muscle. J Appl Physiol. 1996;80:261–70.PubMedGoogle Scholar
  91. Folch J, Lees M, Sloan-Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226:497–509.PubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement